QUARTERLY REPORT
H1 FY2026 — Results booklet
H1 FY2026PDF · 81 pages1.7 MB
.
-- 1 of 81 --
1 Commentary
10 Group statement of financial position
11 Group income statement
12 Group statement of other
comprehensive income
13 Group statement of cash flows
14 Group statement of changes in equity
A.
17 A.1 Segment information
26 A.2 Normalised profit from operations
26 A.3 Earnings, headline earnings and
normalised headline earnings
28 A.4 Revenue from non-insurance activities
28 A.5 Borrowings at amortised cost
30 A.6 Fair value hierarchy
B.
34 B.1 Exchange rates to the South African rand
used in the preparation of these results
34 B.2 Capital management, financial leverage
ratio and covenants
36 B.3 Impact of financial risk variances within
the SA Life and UK Life operating
segments
36 B.4 Cash and cash equivalents
37 B.5 Consolidation of Discovery Unit Trusts
37 B.6 Material transactions with related parties
37 B.7 Major customers and other Discovery
entities not part of Discovery Group
37 B.8 Changes in directorate
38 B.9 Events after reporting date
C.
40 C.1.1 Insurance and reinsurance contracts
disclosures and reconciliations
44 C.1.2.1 Summary of insurance contracts issued
and reinsurance contracts held
45 C.1.2.2 Summary of movements
48 C.1.2.3 Movement in insurance contract
balances: GMM
54 C.1.2.4 Movement in insurance contract
balances: VFA
56 C.1.2.5 Movement in reinsurance contract
balances: GMM
60 C.1.2.6 Insurance revenue
62 C.1.2.7 Net investment result
66 C.1.2.8 Effect of contracts initially recognised
in the period
D.
70 D.1 Restatement as a result of prior period
errors identified
E.
74 E.1 New Accounting Standards and
amendments to published Accounting
Standards not yet effective
74 E.2 Normalised headline earnings
75 E.3 Basis of preparation
78 Table 1: Group embedded value
80 Table 2: Value of in-force covered business
81 Table 3: Group embedded value earnings
81 Table 4: Components of Group embedded value
earnings
82 Table 5: Experience variances
83 Table 6: Methodology and assumption changes
84 Table 7: Value of new business
86 Table 8: Embedded value economic assumptions
88 Table 9: Embedded value sensitivity
88 Table 10: Value of new business sensitivity
91 New business annualised premium income
92 Income from non-insurance business lines
92 Cash conversion ratio
IBC Administration
A
B
D
Contents
Discovery Limited
Registration number 1999/007789/06
Notes to the Interim results D Adoption of new standards and
interpretations and restatements
B Other significant items in
these results
C Insurance and reinsurance
contracts related disclosures
E Accounting policies
Embedded value statement
Annexure A
-- 2 of 81 --
Commentary
Discovery Group achieved strong growth in the period ended 31 December 2025, evidenced by a
24% growth in normalised operating profit to R8 891 million. Headline earnings increased by
29% to R5 692 million and normalised headline earnings increased by 27% to R5 745 million,
resulting in the normalised return on equity increasing to 17.4%, from 15.4% in the prior period.
1. GROUP OVERVIEW AND SALIENT RESULTS
SALIENT GROUP RESULTS FOR THE PERIOD ENDED 31 DECEMBER 2025
The Group delivered a strong performance in an environment characterised by increased complexity as a result of geopolitical and trade
tensions. In the period under review, economic growth remained below potential in many regions in which the Group operates; however,
easing interest rates supported an improved backdrop for investment markets. Specifically in South Africa (SA), constructive collaboration
between private and public enterprise in key areas of service delivery and improved terms of trade have provided a more supportive
backdrop for macro-economic and capital market indicators with green-shoots appearing, resulting in strong capital markets and lower
bond yields. Fiscal challenges in the United Kingdom (UK) have led to pressure on National Health Service (NHS) delivery and a higher
inheritance tax burden. While these macro challenges do constrain economic growth, they also drive increased demand for private health
insurance as well as life insurance for estate planning purposes. Globally, healthcare inflation remained elevated, compounded by growing
demographic challenges and the acceleration of the “quantified self” leading to a rapidly developing wellness economy; both trends are
particularly pronounced in the United States (US). Risks also remain elevated; however, the velocity of AI disruption underpins the relevance
of the Vitality Shared-value model and the Group’s unique data, positioning it uniquely for continued growth.
Unit
31 December
2025
31 December
2024 % Change
Group earnings1
Normalised profit from operations R million 8 891 7 188 24%
Normalised headline earnings R million 5 745 4 511 27%
Headline earnings R million 5 692 4 428 29%
Basic earnings per share Cents 846.6 661.3 28%
Basic headline earnings per share Cents 850.0 667.1 27%
Basic normalised headline earnings per share Cents 858.0 679.6 26%
Returns, cash conversion and dividends
Normalised return on equity (RoE)1 % 17.4 15.4 +2%
Annualised return on opening embedded value (RoEV) % 17.3 19.0 lower by 1.7%
Dividend per share for the period Cents 111 87 28%
Cash conversion2 % 71 76 lower by 5%
Growth drivers
Income from non-insurance business lines2 R million 3 567 3 181 12%
New business annual premium income (API)2 R million 14 026 12 534 12%
Unit
31 December
2025
30 June
2025
% Change
(annualised)
Financial position and embedded value
Net asset value R million 73 438 65 699 25%
Embedded value R million 135 844 126 554 15%
Basic embedded value per share R 201.97 189.85 13%
Financial leverage ratio (FLR) % 15.1 16.8 lower by 1.7%
1 Restated: Refer to D.1.
2 Refer to Annexure A, which also includes details on the restatement of the cash conversion.
1
-- 3 of 81 --
1. GROUP OVERVIEW AND SALIENT RESULTS continued
STRONG PERFORMANCE FROM BOTH COMPOSITES WITH CONTINUED DELIVERY AHEAD
OF THE FIVE-YEAR GROWTH CORRIDOR TARGETS
Over the period, the Group continued to execute its growth strategy, delivering 24% growth in normalised profit from operations. Discovery
SA delivered 19% growth in normalised profit from operations, reflecting a compelling contribution from each business in SA. Vitality
generated 41% growth in normalised profit from operations, reflecting the focus and strong execution within the restructured global
operations. Headline and normalised headline earnings increased by 29% and 27%, respectively, reflecting the benefit of the improving
financial leverage ratio (FLR) translating into lower finance charges.
EVOLVING THE VITALITY SHARED-VALUE (SV) MODEL TO DELIVER HYPER-PERSONALISED
ENGAGEMENT AND VALUE
The successful deployment of the SV model had a significant impact across both the SA and global composites, and within each business of
each composite. This manifested in superior margins for the short-term insurance businesses, superior returns on capital for the long-term
insurance businesses with strong actuarial outcomes, and scalable growth in value for Discovery Bank.
The Group’s continued investment in and deployment of artificial intelligence (AI) into the platforms provide a clear opportunity to propel
the model forward into a new phase, with demonstrable increases in engagement and outcomes in some of the early developments, like
Personal Health Pathways (PHP).
Over the period, the Group’s embedded value increased to R135.8 billion, a 17.3% return on embedded value (RoEV), driven by strong
operational performance. Total new business API increased 12%, reflecting the strong competitive dynamics of the SV model, with a focus
on deliberate and disciplined pricing strategies, resulting in an improved new business value. Favourable experience variances increased
for the period, with positive contributions from each business, reflecting the positive financial dynamics of the model and particularly
strong underlying claims dynamics of the in-force pool of clients across the businesses. Lower bond yields resulted in a positive impact of
economic basis assumptions, which offset lower translated values of foreign operations given the stronger rand, with a favourable
contribution in aggregate.
INCREASED FINANCIAL FLEXIBILITY IN A COMPLEX ENVIRONMENT
Capital ratios remained strong across every regulated business and the strong operating cash generation and improving FLR provided the
Group with significant financial flexibility. The Group recently announced the intention to purchase Discovery’s head office building,
1 Discovery Place. The transaction includes cancelling a portion of the remaining lease, with a total consideration of R4.05 billion (exclusive
of VAT) and is subject to Competition Authority approval and other customary suspensive conditions. The acquisition is to be fully funded
through pre-arranged debt and provides strong financial and economic benefits to the Group.
SUMMARY OF NORMALISED PROFIT FROM OPERATIONS AND NEW BUSINESS
PERFORMANCE FOR THE CURRENT PERIOD:
R million
Normalised
profit from
operations
%
change
New business
API
%
change
Discovery Health 2 128 5% 5 454 16%
Discovery Life1 3 093 15% 1 635 (1%)
Discovery Invest1 984 1% 1 961 13%
Discovery Insure 546 34% 646 (2%)
Discovery Bank 75 <(100%)
Other initiatives and central costs2 (51) (80%) 246 (4%)
Discovery SA composite 6 775 19% 9 942 10%
VitalityHealth 1 186 98% 1 440 9%
VitalityLife 352 8% 1 495 36%
Vitality Network 176 (48%)
Ping An Health Insurance (PAHI) 573 35% 1 149 6%
Vitality Health International Other (16) (89%)
Vitality AI3 (155) >100%
Vitality composite 2 116 41% 4 084 16%
Normalised profit from operations 8 891 24%
New business API 14 026 12%
1 Restated: Refer to D.1.
2 Includes Discovery Vitality SA.
3 Vitality AI also includes other central costs.
2 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Commentary continued
-- 4 of 81 --
2. Business-specific performance
DISCOVERY SA
Discovery SA increased normalised operating profit by 19% to R6 775 million. New business volumes increased
by 10% to R9 942 million. Discovery Bank (DB) continued to expand its capabilities, innovative product solutions
and quality customer base, with more than 70% of new bank clients now also being new to the Group,
demonstrating the Bank’s expanding relevance beyond the core Discovery client base. DB is a key strategic
platform, powered by data, technology and AI, to drive further growth through Discovery SA’s 6.5 million client
base, which increased 7% compared with the prior period. The composite delivered a strong improvement in
central and Vitality programme costs and improved customer engagement levels.
DISCOVERY BANK Unit
December
2025
December
2024
%
Change
Net non-interest revenue (NIR) R million 848 611 39%
Net Interest income (NII)1 R million 623 489 27%
Operating profit before new business acquisition costs R million 319 69 >100%
Normalised profit/(loss) from operations R million 75 (145) >100%
Retail deposits R billion 25.7 21.2 21%
Gross retail advances R billion 11.1 7.8 42%
Average interest-earnings assets (IEA)1 R billion 26.9 21.6 25%
Credit loss ratio (CLR)2 % 2.69 3.01 11%
Number of accounts Million 3.37 2.61 29%
Number of clients Million 1.40 1.09 28%
1 Average interest-earning assets (IEA) = treasury assets + retail banking activities; NII includes the allocation of interest earned on the bond trading portfolio (recognised
as fair value gains in the income statement)
2 CLR calculated as the expected credit loss (ECL) charge, including overlays and IFRS adjustments, on the period-end advances balance across the products.
Discovery Bank (DB) continued its strong momentum, with normalised profit R220 million better than the prior-period loss of
R145 million, and operating profit before new business acquisition costs improving by R250 million, ahead of plan. DB’s total client
base grew 28%, with a further acceleration in the acquisition of clients, currently averaging approximately 1,500 clients per day.
Strong performance across key metrics illustrates the consistent quality of clients and their levels of engagement and primacy.
Non-interest revenue increased 39%, driven by client growth and higher product take-up and engagement across the SV model,
which lifted fee income per client. Expenses benefitted from growing economies of scale, with operating leverage improving as the
book expanded. Efficiency gains from increased use of AI and automated service channels drove efficiencies despite a larger client
base, while the introduction of TRUST Alerts strengthened fraud prevention for clients.
Deposits increased 21% from December 2024, and advances grew 42%, supported by strong growth in home loans (R2.9 billion at the
end of the period) and a 48% increase in the Revolving Credit Facility, contributing to a 27% year-on-year increase in NII.
DISCOVERY HEALTH Unit
December
2025
December
2024
%
Change
Normalised profit from operations R million 2 128 2 023 5%
New business API R million 5 454 4 714 16%
Revenue1 R million 6 181 5 737 8%
Non-scheme revenue as % of total revenue1 % 17.8 15.3 16%
Lives under administration1 Million 3.86 3.79 2%
1. Refer to A.1: Restated to exclude HealthyCompany, which is now included within CEB (Discovery Life).
Discovery Health’s (DH) operating profit increased by 5%, delivering excellent cost efficiency and scalability in the period, while fully
absorbing a once-off administration fee concession to members of R125 million. Alongside this, the business has continued its
investment in technology, AI and strategic adjacencies.
Performance was underpinned by strong new business API, the continued success of the Active Smart Plan within Discovery Health
Medical Scheme (DHMS), and membership growth across LA Health Medical Scheme. Non-medical scheme offerings remain an
important growth vector, with non-scheme revenue increasing to 17.8% of total DH revenue.
DHMS continued to demonstrate resilience, achieving membership growth in a challenging macro-economic environment. The
Scheme’s financial position remains strong, with projected unaudited 2025 solvency of 32.6%, well above the 25% statutory
requirement.
3
-- 5 of 81 --
DISCOVERY LIFE Unit
December
2025
December
2024
%
Change
Normalised profit from operations1 R million 3 093 2 686 15%
New business API1 R million 1 635 1 655 (1%)
New business APE2 R million 411 355 16%
Premium income R million 9 862 9 388 5%
Insurance revenue (IFRS 17) R million 9 798 9 437 4%
Solvency ratio % 180 183
RoEV3 % 31 21
VNB margin % 4.3 3.6
New business net value4 R million 930 886 5%
1 Restated: Refer to D.1; Includes Group Risk and Umbrella (part of Corporate and Employee Benefits (CEB) offerings).
2 New business annual premium equivalent (APE) – refer to embedded value statement.
3 Including Discovery Invest.
4 Calculated as: New business contractual service margin (CSM) + risk adjustment (RA) minus onerous new business.
Discovery Life’s (DL) operating profit increased by 15% to R3 093 million. Individual Life profit was up 6%, driven by favourable overall
experience. Corporate and Employee Benefits (CEB) delivered a strong profit increase of 129%, driven by favourable claims experience as
well as Umbrella turning profitable over the period.
During the period leading up to December 2025, long-term interest rates in South Africa decreased significantly. This led to a material
gain, of approximately R8 billion, in the present value of projected fulfilment cash flows, with the gain reflected through Other
Comprehensive Income (OCI), a component of equity, rather than being recognised directly in earnings.
New business APE, measured as per the Embedded Value (EV) statement, grew 16% to R411 million, which included a recovery from
Group Risk. New business API declined slightly – a result of lower inflation rates on automatic contribution increases (ACIs) compared to
the prior period and lower Umbrella Fund sales, both of which are not incorporated into the measure of new business in the EV basis.
The VNB margin of 4.3% improved significantly from 3.6% in the prior period and 2.1% in June 2025, primarily due to the lower interest
rates.
Discovery Life Limited (including Discovery Invest) delivered positive variances, generating an annualised RoEV of 31%, or 14%, excluding
the impact of lower interest rates. Continued favourable claims experience offset the net impact of lapse and policy alterations
experience for Individual Life, which was largely consistent with the projected action plan. Retention at CEB declined slightly in a
competitive market. The business remains focused on managing the negative policy alterations experience according to a well-defined
strategy.
Discovery Life Limited’s (including Discovery Invest) cash generation increased further, to R1 628 million (prior half-year R1 497 million),
before a R616 million net repayment of financing arrangements (prior period R981 million).
4 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Commentary continued
-- 6 of 81 --
DISCOVERY INVEST Unit
December
2025
December
2024
%
Change
Normalised profit from operations1 R million 984 972 1%
Assets under administration R billion 200 167 20%
Assets under management R billion 142 115 24%
% linked assets in Discovery funds % 81 81 0%
Net client cash flows R billion 2.6 2.4 8%
New business API R million 1 961 1 735 13%
New business APE2 R million 1 467 1 234 19%
1 Restated: Refer to D.1.1.
2 New business annual premium equivalent (APE) – refer to embedded value statement.
Discovery Invest increased operating profit by 1% to R984 million. Assets under management and assets under administration
increased 24% and 20%, respectively, as a result of strong market performance and positive net inflows. The rate of earnings growth
was dampened by an in-period asset-liability matching (ALM) loss (R87 million) related to the steep decline in yields, following the
prior period ALM gain (R85 million). Excluding the ALM movements, earnings increased 21%, in line with the growth in average assets
under management.
Robust growth in new business followed strong sales of linked business, offset partly by lower sales of guaranteed products, as the
lower interest-rate environment made these products less attractive.
DISCOVERY INSURE Unit
December
2025
December
2024
%
Change
Discovery Insure normalised profit from operations R million 487 378 29%
Equity accounted profit/(loss) R million 59 29 >100%
Normalised profit from operations R million 546 407 34%
Operating margin % 15.2 12.3 24%
New business API R million 646 659 (2%)
Insurance revenue R million 3 207 3 078 4%
Discovery Insure delivered an excellent performance, with normalised profit from operations increasing 29% to R487 million and
total normalised profit from operations rising 34% to R546 million. Rigorous implementation of the Vitality Shared-value model
resulted in a substantial increase in operating margin, to 15.2%, notwithstanding weather conditions worsening from a benign prior
period. Specific focus on pricing and claims management drove continued improvement in the underlying book, while maintaining
quality of new business.
Motor accident claims were significantly below budget, reflecting the continued impact of the Vitality Drive programme, with
improved driving-status profiles across durations and calendar periods. The growth in insurance revenue was supported by the
resilience of the in-force book and the slight decline in new business is consistent with the disciplined pricing stance in a softening
market cycle.
5
-- 7 of 81 --
VITALITY (UNITED KINGDOM AND VITALITY GLOBAL)
Vitality’s normalised operating profit increased by 41% to R2 116 million, off the back of exceptional
performances in both the UK and China. New business API increased by 16% to R4 084 million. Vitality now
covers 11.2 million lives outside China, up 15% over the year, including more than two million clients in the UK.
Ping An Health Insurance’s (PAHI) lives increased 17%, exceeding 34 million.
All the global operations have now been successfully restructured into a single focused business, through a
regionalised operating model that can effectively deploy and efficiently scale its capabilities. The investment into
Vitality AI has accelerated over the period, anticipated to drive increased efficiency in the Vitality programmes
globally, accelerate traction in existing partnerships and enhance the value from new partnerships. Vitality
unveiled its partnership with Google in November 2025, combining Google’s secure, scalable cloud and AI
capabilities with Vitality’s unique data assets and leadership in incentivised behaviour change and shared-value
insurance to deliver precise and personalised health improvement actions at scale.
In Vitality UK, VitalityHealth benefitted from its focused model-driven repricing and VitalityLife generated
excellent new business returns, both successfully deploying the Vitality Shared-value model. Vitality Network
focused on restructuring existing partnerships and delivering new European partnerships, with investment to
ensure the business is well positioned for growth and long-term value creation. Vitality Health International
focused on continued scaling through quality profits within Ping An Health Insurance, while growing its own
distribution channels and Vitality Health USA and Amplify Health focused on deploying superior capabilities and
driving traction towards operational profitability.
VITALITY HEALTH Unit
December
2025
December
2024
%
Change
Normalised profit from operations £ million 50.9 25.9 97%
R million 1 186 599 98%
Insurance revenue (earned premiums) £ million 450.8 393.8 14%
R million 10 498 9 112 15%
New business API1 £ million 61.8 57.3 8%
R million 1 440 1 326 9%
Lives covered Million 1.06 1.04 2%
1 Refer to Annexure A.
VitalityHealth's (VH) operating profit rose by 97% to £50.9 million (98% to R1 186 million), reflecting its strong recovery. The business is
tracking ahead of the run rate required to achieve its 7.5% margin guidance for the current financial year, driven by effective pricing, a
stable claims environment and particularly strong claims and expense management in this period. Premiums remain aligned to claims
experience, notwithstanding ongoing challenges in the National Health Service.
New business growth of 8%, in a challenging macro-economic environment with heightened price competition, was supported by
advanced price optimisation and a diversified distribution capability. Consistent with the strategy to rebase premiums and restore
margins, retention efforts focused on maintaining high-quality business at appropriate pricing. Together with new business, this
supported a 14% increase in earned premiums, while net lives growth of 2% was more moderate. VH continued to invest in healthcare
risk management, primary care assets and digital servicing to enhance cost efficiency and care outcomes.
6 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Commentary continued
-- 8 of 81 --
VITALITY LIFE Unit
December
2025
December
2024
%
Change
Normalised profit from operations £ million 15.1 14.1 7%
R million 352 327 8%
Earned premiums £ million 247.6 216.8 14%
R million 5 767 5 016 15%
New business API £ million 64.2 47.6 35%
R million 1 495 1 101 36%
New business APE1 £ million 53.5 39.8 34%
R million 1 245 921 35%
Insurance revenue £ million 190.2 162.4 17%
R million 4 429 3 758 18%
Lives covered Million 0.958 0.852 12%
VNB margin % 2.2 0.9
New business net value2 £ million 34.6 24.3 42%
R million 805 562 43%
1 New business annual premium equivalent (APE) - refer to embedded value statement
2 New business net value (NB CSM + NB RA minus onerous NB) excludes the impact of new reinsurance contracts attaching to the in-force book in the year. The total CSM
and RA on all contracts incepted in the year was £37.3 million (R831 million).
VitalityLife’s (VL) operating profit rose by 7% to £15.1 million (8% to R352 million), reflecting the unwind in margins, with stable lapse
and claims experience from sustained member engagement in the Vitality programme and its positive impact on actuarial dynamics.
VL maintained its exceptional sales trajectory, with new business increasing by 35%. The UK market showed signs of growth, and VL
continued to execute the Vitality Shared-value model effectively through an expanded distribution footprint, supporting both volume
growth and improved new business quality. Together with disciplined expense management, this resulted in a 42% increase in new
business net value. Robust retention, combined with strong new business volumes, increased lives covered by 12% and earned
premiums by 14%.
VITALITY GLOBAL
VITALITY NETWORK Unit
December
2025
December
2024
%
Change
Revenue US$ million 47.8 54.1 (12%)
R million 831 970 (14%)
Normalised profit from operations US$ million 10.2 18.9 (46%)
R million 176 339 (48%)
Operating margin % 21 35 (40%)
Integrated API by Insurance Partners US$ million 1 026 910 13%
R million 17 843 16 304 9%
Number of lives Million 6.9 6.2 11%
Vitality Network’s (VN) normalised operating profit decreased by 46% to US$10.2 million (48% to R176 million), significantly impacted
by adverse economics from foreign exchange movements, primarily in the weakening of the USD/JPY and higher Japanese interest
rates, resulting in losses of US$7.5 million in aggregate, versus prior period gains of US$1.5 million (and $4 million gains in FY2025).
The consistent and exceptional performance of Sumitomo Life has driven an expanded Yen-denominated contract asset, which is
expected to unwind at a high rate, but which gave rise to earnings volatility through its currency translation in the current period.
Excluding the impact of these economics, profits increased 7%, reflecting the investment underway to build greater longer-term
scale and value.
Vitality-integrated new business increased 13% to approximately US$1.03 billion and membership increased 11% to 6.9 million,
demonstrating the growing global relevance of the model. Lower solutions revenues and licence fees impacted the growth in
revenues, which were up 2% excluding the impact of the above economics, and down 12% in total.
Following the establishment of the global Vitality composite, the business restructured its operating model and partnerships to
further monetise its unique global position. In particular, the termination of the partnership with Generali has opened the large
European markets where Vitality is actively pursuing multiple new long-term partnerships.
7
-- 9 of 81 --
PING AN HEALTH INSURANCE (PAHI)
Discovery interim results PAHI full-year (12-month) period2
Unit
December
2025
December
2024
%
Change
December
2025
December
2024
%
Change
PAHI after-tax operating profit
(25%), after Discovery’s costs R million 573 424 35% 1 355 1 204 13%
PAHI pre-tax profit (100%) RMB million 1 444 906 59% 3 082 2 439 26%
Profit before investment income
and gains (100%) RMB million 682 306 123% 1 773 1 420 25%
Investment income and gains
(100%) RMB million 762 599 27% 1 309 1 018 29%
New business (100%)1 RMB million 1 883 1 743 8% 4 947 3 994 24%
New business (25%)1 R million 1 149 1 088 6% 3 084 2 547 21%
Written premium (100%)1 RMB million 8 271 7 452 11% 19 642 17 036 15%
Earned premium (100%)1 RMB million 9 500 8 286 15% 18 243 15 904 15%
Lives1 Million 34.1 29.1 17% 34.1 29.1 17%
Investable assets RMB million 27.6 24.6 12% 27.6 24.6 12%
1 PAHI own licence business.
2 PAHI full-year calendar performance has been included to align with the Chinese industry comparable reporting.
The Group’s share of PAHI’s after-tax operating profit increased 35% to R573 million for the six-month period. The strong operational
result was delivered by disciplined cost control, regulatory-driven reductions in distribution costs, and stable retention. A surge in the
Shanghai Stock Exchange resulted in an exceptional investment result for the period. PAHI maintained a solid financial position, with
an unaudited comprehensive solvency ratio of 312% in Q4 CY2025. Profitability was further enhanced by product innovation and
deeper integration of health and wellness features, resulting in a 13% net margin for the calendar year. From January 2026, the
margin is likely to be negatively impacted by changes relating to dividend tax credits, expected to impact PAHI’s CY2026 net profit by
approximately RMB200 million.
New business written under the PAHI insurance licence grew 8% over six months (24% over 12 months), supported by increased
volumes from online third-party channels. Direct written premiums rose 11% over six months, driven by sustained new business
growth and improving retention across all channels, and 15% for CY2025, 9% faster than the industry. As of December 2025, directly
insured lives increased 17%, exceeding 34 million.
New business growth was impacted by recent changes implemented to its distribution arrangement with Ping An Life (PAL), another
Ping An Group subsidiary. In response to regulatory requirements pertaining to related parties, PAL discontinued its distribution of
PAHI’s main eShengBao product range, accounting for approximately 22.5% of new business at the time (September 2025). This will
affect new business production in the short term but is being ameliorated by PAHI’s rapidly growing multi-channel distribution
capability, and a widening product range. Existing eShengBao in-force policies that were sold by PAL will remain with PAHI and the
impact on PAHI's operating profits is expected to be largely mitigated. PAL and PAHI are establishing new commercial arrangements,
aligned with the regulations, both for services provided by PAHI to PAL and for the distribution of other PAHI products.
Both Ping An Group and Discovery remain confident in PAHI’s long-term growth prospects, underpinned by strong momentum in
product innovation, channel diversification, and a supportive regulatory environment in China.
VITALITY HEALTH INTERNATIONAL – OTHER
Vitality Health International (VHI) Other made rapid progress towards profitability, with losses decreasing significantly to $1 million,
driven by smaller losses in Vitality Health USA and Amplify Health.
Vitality Health USA continues to evolve from a traditional employee wellness provider to offering comprehensive, integrated digital
health and care solutions to health plans and employers. The acquisition of WellSpark, a personalised coaching business, in
November 2024 has exceeded expectations, contributing to the improved result. The business has developed a broad set of
customised wellbeing, coaching and disease prevention services, and has deployed Vitality AI to EmblemHealth, New York’s leading
health plan provider. The business continues to make progress in its sales to health plans, including to Blue Cross Blue Shield plans,
and to the significant Medicare Advantage market, as total membership reached 2.4 million at the end of the period.
Amplify Health continued to deliver award-winning, AI-enabled and data-driven health-tech products and solutions across the
Asia-Pacific region. The business had successful deployments in multiple Asia-Pacific markets, across all its main products, including
its core claims system, and is prioritising further deployment of an integrated suite of products in key AIA markets.
8 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Commentary continued
Unit
December
2025
December
2024
%
Change
Revenue US$ million 28 25.9 8%
R million 487 465 5%
Normalised profit from operations US$ million (1) (8.3) (88%)
R million (16) (149) (89%)
-- 10 of 81 --
Prospects and dividend
Discovery’s growth strategy is based on the efficacy, repeatability and scalability of its model through organic growth and global
partnerships. The acceleration of technological and demographic trends reinforces the relevance of the model and Discovery’s unique data.
The Group is well positioned for sustained growth through focused composites; Discovery South Africa and Vitality, with strong platforms in
each, resulting in growth in earnings, cash generation, and return on equity, as well as lower leverage. The Group established a five-year
ambition for normalised profit from operations to grow between 15% to 20% on a compound basis from the end of 2024 to 2029. The
strong underlying momentum and performance in the first half of 2026 has further increased the Group’s confidence in achieving this
ambition.
In terms of the Group’s current dividend policy and guidance, annual ordinary dividends are expected to be covered approximately five
times by normalised headline earnings, with interim ordinary dividends expected to be paid in the range of 30% to 40% of the expected
total annual ordinary dividend. In line with this, the Group has declared its interim ordinary dividend for the period at 111 cents per share,
up 28% following the growth in normalised headline earnings.
Notes to Analysts
Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company's external
auditors.
Discovery has published supplemental unaudited information on the website. For this and other results information, visit
https://www.discovery.co.za/corporate/investor-relations and go to Financial and annual reports.
On behalf of the Board
ME Tucker A Gore
Chairperson Group Chief Executive
Sandton
2 March 2026
9
-- 11 of 81 --
R million
December
2025 June 2025
Assets
Goodwill 5 172 5 429
Intangible assets 7 206 7 542
Property and equipment 3 075 3 266
Assets arising from insurance contracts issued 58 241 48 047
Assets arising from reinsurance contracts held 978 962
Deferred tax asset 4 239 4 886
Assets arising from contracts with customers 3 677 3 722
Investment in equity-accounted investees 9 322 8 989
Financial assets
– Loans and advances to customers at amortised cost 11 705 8 513
– Investments at amortised cost 13 609 12 812
– Investments at fair value through other comprehensive income – 14
– Investments at fair value through profit or loss 216 868 193 776
– Derivative financial instruments at fair value through profit or loss 83 63
Contract receivables and other receivables 7 441 7 368
Non-current assets held for sale – 62
Current tax asset 41 31
Cash and cash equivalents 20 767 21 968
TOTAL ASSETS 362 424 327 450
Equity
Capital and reserves
Ordinary share capital and share premium 12 121 11 358
Perpetual preference share capital 779 779
Other reserves 7 588 4 921
Retained earnings 52 956 48 646
Equity attributable to equity holders of the Company 73 444 65 704
Non-controlling interest (6) (5)
TOTAL EQUITY 73 438 65 699
Liabilities
Liabilities arising from insurance contracts issued 133 095 118 878
Liabilities arising from reinsurance contracts held 10 354 9 121
Deferred tax liability 11 454 8 755
Contract liabilities to customers 1 567 1 516
Third-party interest in consolidated funds 40 319 35 932
Financial liabilities
– Borrowings at amortised cost 19 479 20 046
– Other financial payables at amortised cost 7 357 9 148
– Deposits from customers 25 726 23 326
– Investment contracts at fair value through profit or loss 36 794 32 188
– Derivative financial instruments at fair value through profit or loss 287 135
Other payables 2 210 2 333
Current tax liability 344 373
TOTAL LIABILITIES 288 986 261 751
TOTAL EQUITY AND LIABILITIES 362 424 327 450
10 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Group statement of financial position
as at 31 December 2025
-- 12 of 81 --
R million
December
2025
Restated
December
20241 June 2025
Insurance revenue 30 700 27 925 57 713
Insurance service expenses (25 064) (23 483) (49 028)
Net expenses from reinsurance contracts (961) (866) (1 306)
Insurance service result 4 675 3 576 7 379
Net financial result from insurance finance income and expense (12 470) (6 082) (13 088)
– Net finance expense from insurance contracts (12 332) (5 892) (12 665)
– Net finance expense from reinsurance contracts (138) (190) (423)
Investment income using the effective interest rate method 526 461 998
Net fair value gains on financial assets at fair value through profit or loss 22 263 12 637 25 818
Fair value adjustment to liabilities under investment contracts (3 338) (1 919) (3 810)
Third party interest: fair value adjustment to liabilities under investment contracts (4 068) (2 401) (4 394)
Other gains on financial instruments – (9) (9)
Net insurance and investment results 7 588 6 263 12 894
Fee income from administration businesses 7 026 7 031 14 326
Vitality income 2 802 2 618 5 322
Net banking fee and commission income 990 731 1 695
– Banking fee and commission income 1 334 1 036 2 238
– Banking fee and commission expense (344) (305) (543)
Net banking interest and similar income 590 489 966
– Banking interest and similar income using the effective interest rate 1 243 1 105 2 203
– Banking interest and similar expense using the effective interest rate (653) (616) (1 237)
Other income 1 021 936 1 832
Non-insurance revenue and income 12 429 11 805 24 141
Net income 20 017 18 068 37 035
Non-insurance acquisition costs (188) (317) (384)
Expected credit losses (150) (118) (279)
Marketing and administration expenses (11 092) (10 533) (21 765)
Impairment of goodwill – – (20)
Operating profit 8 587 7 100 14 587
Loss on dilution and disposal of equity-accounted investments – (26) (32)
Share of net profits from equity-accounted investments 707 399 1 215
Profit before financing and income tax 9 294 7 473 15 770
Interest expenses on borrowings and lease liabilities (937) (1 094) (2 087)
Foreign exchange (losses)/gains (83) 13 (36)
Profit before income tax 8 274 6 392 13 647
Income tax expense (2 515) (1 900) (4 089)
Profit for the period/year 5 759 4 492 9 558
Profit attributable to:
– Ordinary shareholders 5 716 4 448 9 471
– Preference shareholders 44 47 93
– Non-controlling interest (1) (3) (6)
5 759 4 492 9 558
Earnings per share for profit attributable to ordinary shareholders of the
company during the period/year (cents):
– Basic 846.6 661.3 1 402.2
– Diluted 842.7 658.0 1 394.9
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual financial
statements for the year ended 30 June 2025. Refer to D.1 for more details.
11
Group income statement
for the six months ended 31 December 2025
-- 13 of 81 --
R million
December
2025
Restated
December
20241 June 2025
Profit for the period/year 5 759 4 492 9 558
Income and expenses that will be reclassified to profit or loss when specific
conditions are met:
Currency translation differences (2 168) 577 998
– Unrealised (losses)/gains (2 233) 589 1 032
– Tax on unrealised losses/(gains) 65 (12) (34)
Cash flow hedges (72) (40) (104)
– Unrealised losses (74) (40) (106)
– Gains reclassified to profit or loss 2 – 2
Net finance income/(expense) from insurance contracts issued 6 398 2 060 2 186
– Unrealised income/(expense) 8 746 2 810 2 961
– Tax on unrealised (income)/expense (2 348) (750) (775)
Net finance (expense)/income from reinsurance contracts held (530) (67) (282)
– Unrealised (expense)/income (724) (90) (382)
– Tax on unrealised expense/(income) 194 23 100
Share of other comprehensive income from equity-accounted investments (506) 301 (120)
– Change in fair value of debt instruments at fair value through other
comprehensive income (62) 49 16
– Currency translation differences (444) 252 (136)
Total income and expenses that will be reclassified to profit or loss when
specific conditions are met 3 122 2 831 2 678
Income and expenses that will not be reclassified to profit or loss:
Equity instruments held at fair value through other comprehensive income – – (2)
– Change in fair value of equity instruments at fair value through other
comprehensive income – – (2)
– Tax on change in fair value of equity instruments at fair value through other
comprehensive income – – *
Share of other comprehensive income/(loss) from equity-accounted
investments 22 (5) 23
– Change in fair value of equity instruments at fair value through other
comprehensive income 22 (5) 23
Total income and expenses that will not be reclassified to profit or loss 22 (5) 21
Other comprehensive income for the period/year, net of tax 3 144 2 826 2 699
Total comprehensive income for the period/year 8 903 7 318 12 257
Attributable to:
– Ordinary shareholders 8 860 7 274 12 169
– Preference shareholders 44 47 93
– Non-controlling interest (1) (3) (5)
Total comprehensive income for the period/year 8 903 7 318 12 257
* Amount is less than R500 000.
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual financial
statements for the year ended 30 June 2025. Refer to D.1 for more details.
12 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Group statement of other comprehensive income
for the six months ended 31 December 2025
-- 14 of 81 --
R million
December
2025
Restated
December
20241 June 2025
Cash flows from operating activities 1 965 3 546 8 667
Cash (utilised)/generated from operations (4 070) 485 1 289
Interest received 1 589 1 245 2 955
Interest paid (1 574) (1 494) (2 877)
Taxation paid (1 337) (758) (1 867)
Net movement in operating assets and liabilities 7 357 4 068 9 167
– Increase in operating assets (6 846) (5 005) (11 060)
– Increase in operating liabilities 14 203 9 073 20 227
Cash flows from investing activities (812) (1 304) (1 823)
Purchase of property and equipment (145) (120) (294)
Proceeds from disposal of property and equipment 2 3 3
Purchase of intangible assets (735) (875) (1 682)
Acquisition of business and subsidiaries net of cash – (304) (316)
Proceeds from disposal of sale of non-current asset held for sale 59 –
Additional investment in equity-accounted investments (3) (11) (24)
Dividends from equity-accounted investments 10 3 490
Cash flows from financing activities (1 765) (1 938) (4 016)
Dividends paid to ordinary shareholders (1 363) (1 026) (1 614)
Dividends paid to preference shareholders (44) (47) (93)
Proceeds from borrowings 2 592 1 765 3 264
Repayment of borrowings (2 950) (2 630) (5 573)
Net (decrease)/increase in cash and cash equivalents (612) 304 2 828
Cash and cash equivalents at beginning of the period/year 21 966 18 965 18 965
Effects of exchange rate changes on cash and cash equivalents (587) 90 173
Cash and cash equivalents at end of the period/year 20 767 19 359 21 966
Reconciliation to statement of financial position
Cash and cash equivalents 20 767 19 359 21 968
Bank overdraft included in borrowings at amortised cost – – (2)
Cash and cash equivalents at end of the period/year 20 767 19 359 21 966
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual financial
statements for the year ended 30 June 2025. Refer to D.1 for more details.
13
Group statement of cash flows
for the six months ended 31 December 2025
-- 15 of 81 --
R million
Attributable to equity holders of the Company Attributable to equity holders of the Company
Share capital
and share
premium
Perpetual
preference
share capital
Share-based
payment
reserve
Investment
reserve1
Insurance
finance
reserve
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings Total
Non-
controlling
interest Total Equity
Six months ended 31 December 2025
At beginning of the period - July 2025 11 358 779 1 480 118 (2 928) 6 375 (124) 48 646 65 704 (5) 65 699
Total comprehensive income for the period – 44 – (40) 5 868 (2 612) (72) 5 716 8 904 (1) 8 903
Profit for the period – 44 – – – – – 5 716 5 760 (1) 5 759
Other comprehensive income – – – (40) 5 868 (2 612) (72) – 3 144 – 3 144
Transactions with owners 763 (44) (476) (1) – – – (1 406) (1 164) – (1 164)
Share issue 625 – – – – – – (9) 616 – 616
Increase in treasury shares (625) – – – – – – – (625) – (625)
Delivery of treasury shares 763 – (763) – – – – – – – –
Modification of share based payment settlement – – (95) – – – – (40) (135) – (135)
Changes in ownership interests – – – – – – – 5 5 – 5
Transfer among reserves – – – (1) – – – 1 – – –
Employee share option schemes:
– Value of employee services, net of tax – – 382 – – – – – 382 – 382
Dividends paid to preference shareholders – (44) – – – – – – (44) – (44)
Dividends paid to ordinary shareholders – – – – – – – (1 363) (1 363) – (1 363)
At end of the period 12 121 779 1 004 77 2 940 3 763 (196) 52 956 73 444 (6) 73 438
Six months ended 31 December 2024
At beginning of the period - July 20242 10 667 779 1 433 81 (4 832) 5 514 (20) 40 829 54 451 – 54 451
Total comprehensive income for the period – 47 – 44 1 993 829 (40) 4 448 7 321 (3) 7 318
Profit for the period – 47 – – – – – 4 448 4 495 (3) 4 492
Other comprehensive income – – – 44 1 993 829 (40) – 2 826 – 2 826
Transactions with owners 690 (47) (330) – – – – (1 044) (731) – (731)
Share issue 626 – – – – – – – 626 – 626
Increase in treasury shares (626) – – – – – – – (626) – (626)
Delivery of treasury shares 690 – (672) – – – – (18) – – –
Employee share option schemes:
– Value of employee services, net of tax – – 342 – – – – – 342 – 342
Dividends paid to preference shareholders – (47) – – – – – – (47) – (47)
Dividends paid to ordinary shareholders – – – – – – – (1 026) (1 026) – (1 026) – –
At end of the period 11 357 779 1 103 125 (2 839) 6 343 (60) 44 233 61 041 (3) 61 038
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured
at FVOCI, in terms of IFRS 9 Financial Instruments.
2 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual financial statements
for the year ended 30 June 2025. Refer to D.1 for more details.
14 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 15
Group statement of changes in equity
for the six months ended 31 December 2025
-- 16 of 81 --
S E C T I O N A
Notes to the
Interim results
17 A.1 Segment information
26 A.2 Normalised profit from operations
26 A.3 Earnings, headline earnings and
normalised headline earnings
28 A.4 Revenue from non-insurance activities
28 A.5 Borrowings at amortised cost
30 A.6 Fair value hierarchy
16
-- 17 of 81 --
A.1 SEGMENT INFORMATION
Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker (CODM). The CODM has been identified as the Group Executive Committee who makes strategic decisions
regarding these businesses.
An operating segment is a component of an entity:
(a) That engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses
relating to transactions with other components of the same entity.
(b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to
the segment and assess its performance; and
(c) For which discrete financial information is available.
An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations
may be operating segments before earning revenues.
Discovery will report separately information about an operating segment that meets any of the following quantitative
thresholds:
(a) Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 percent or more
of the combined revenue, internal and external, of all operating segments.
(b) The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount, of (i) the
combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all
operating segments that reported a loss; and
(c) Its assets are 10 percent or more of the combined assets of all operating segments.
Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately
disclosed, if management believes that information about the segment would be useful to users of the financial statements.
Discovery may combine information about operating segments that do not meet the quantitative thresholds with information
about other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the
operating segments have similar economic characteristics.
The Group has identified its reportable segments based on a combination of products and services offered to customers and the
location of the markets served.
17
Disclosure
for the six months ended 31 December 2025
A. Notes to the Interim results
-- 18 of 81 --
A.1 SEGMENT INFORMATION continued
The following summary describes the operations of each of the Group’s reportable segments:
18 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
A. Notes to the Interim results continued
UK HEALTH
Offers consumer-engaged private medical insurance products
to employer groups and individuals in the UK. All contracts in
this segment are short-term insurance contracts.
UK LIFE
Offers a risk-only life assurance product. All contracts in
this segment are long-term assurance contracts offered to
both employer groups and individuals in the UK.
Includes those businesses that are not operating segments, as well as those operating segments that
do not meet the qualitative thresholds for separate reporting. It includes:
Discovery SA
■ SA Vitality, which offers health and lifestyle benefits with
selected partners to the Group’s SA clients.
■ SA Insure commercial: provides commercial short-term risk
insurance products to the South African market. Discovery
announced that it is exiting this business with all remaining
covers terminated by 31 August 2024.
■ SA Distribution: provides sales and distribution services in
respect of all SA products.
■ Discovery Central Services, performing various shared services,
treasury and administrative functions to entities within the
Discovery Group.
■ Other new group initiatives, including Discovery Green, as well
as unallocated central costs.
Vitality
■ Vitality Corporate Services (VCSL): provides
administration, distribution and management services
for entities within the UK Composite.
■ Vitality Health International, leverages Discovery Health
and Vitality’s intellectual property to create strategic
partnerships through equity-accounted interests in
health insurance and health technology and solutions
businesses, which includes the equity-accounted
interests in Ping An Health Insurance and Amplify
Health.
■ Vitality Network, which provides a Vitality platform to
international insurance businesses.
■ Includes Vitality AI spend, immaterial interests in equity-
accounted interests, as well as unallocated central costs.
All other segments
SA HEALTH
■ Administers and provides managed care services to medical
schemes in South Africa.
■ Renders administration services to other business segments within
the Group.
■ Together with Medical Services Organisation International (MSO), a
subsidiary company, delivers health insurance, healthcare risk
management and third-party administration services within rest of
Africa markets.
■ Offers non-medical scheme-related products such as Gap Cover for
unexpected medical costs and Flexicare – which provides quality,
affordable access to primary healthcare for employees unable to
access medical scheme benefits.
SA INVEST
Offers, through a range of investment fund choices, including Discovery
managed unit trusts, a comprehensive and flexible range of investment
choices. These products are sold through a number of investment
wrappers, including Discovery Life policies, and are offered to individuals in
South Africa.
SA LIFE
Offers a range of insurance and financial solutions
to the Group’s clients against the financial impact of
lifestyle-changing events in South Africa. This
segment also includes Corporate and Employee
Benefits (CEB), which comprises the Group Risk,
Umbrella and HealthyCompany offerings.
SA INSURE
Offers a range of personal line insurance (motor,
building, household content and portable
possessions) to the Group’s SA clients against the
financial impact of loss or damage. The segment
also includes SA Insure’s equity-accounted interests
including Cambridge Mobile Telematics (CMT).
SA BANK
Offers retail banking solutions, including deposits
and loans and advances, to clients in the South
African market. The Bank is still in a start-up phase.
2
-- 19 of 81 --
A.1 SEGMENT INFORMATION continued
The Group Executive Committee assesses the performance of the reportable segments based on normalised profit/loss from
operations. Items that are excluded from normalised profit/loss from operations are separately disclosed in the segment
information to reconcile to the segment results and Group income statement. The segment information is presented on the
same basis as reported to the CODM.
The segment total is then adjusted for accounting reclassifications and entries required to produce results compliant with the
IFRS Accounting Standards, i.e. IFRS reporting adjustments. These adjustments include the following:
(a) Unit trusts that the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s
results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s
results, effectively being the income and expenses relating to units held by third parties.
(b) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments; and
(c) The effects of reclassifying items to align to the IFRS Group income statement.
Changes effective from 1 July 2025
1. Effective from 1 July 2025, Discovery has revised the presentation of the ‘Intersegment funding’ charge between SA Invest
and SA Life. Previously, this charge predominantly reflected the cost incurred by SA Invest in backing its liabilities using the
Assets arising from insurance contracts within SA Life. Over recent years, SA Invest has increasingly backed its liabilities
using financial assets it held directly. As a result, the ‘Intersegment funding’ charge now predominantly reflects costs
associated with the service component of providing benefits on integrated SA Life and SA Invest product offerings. To better
reflect the service cost nature of this charge, the charge has been reclassified and is now included within insurance service
expense and other. The comparative information has been restated accordingly. This change in presentation had no impact
on the Group income statement, normalised profit from operations, basic and diluted earnings, or cash flows.
CHANGES EFFECTIVE FROM 1 JULY 2024 AS PREVIOUSLY PUBLISHED IN THE ANNUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025 IMPACTING DECEMBER 2024 RESULTS
2. Prior to 1 July 2024, the Group Risk portfolio of the CEB business was included within the SA Life segment, while the
remainder of the CEB business was reported under All other segments in the segment information. To reflect the
operational and managerial alignment of CEB with SA Life’s business activities and internal reporting structure, the
remainder of CEB business was reclassified to the SA Life segment effective from 1 July 2024. The comparative information
has been restated accordingly, resulting in a R26 million decrease in SA Life’s normalised profit from operations, with a
corresponding increase in All other segments. The change has no impact on the Group’s normalised profit from operations.
3. From 1 July 2024, SA Invest amended the presentation of specified income tax expenses within its business line to improve
the usefulness of the information provided and to enhance comparability with peers in the market. Within its normalised
profit from operations, SA Invest now includes tax expenses specific to policyholder tax funds that are directly chargeable to,
or recoverable from, policyholders. These are also often referred to as ‘policyholder taxes’ or ‘contract holder taxes’. The
comparative information has been restated to reflect this revised presentation.
4. Prior to 1 July 2024, Vitality Drive International (VDI) was included under All other segments. Effective from 1 July 2024 VDI
has been reclassified to the SA Insure segment resulting in an increase in normalised profit from operations of R6 million
and a corresponding decrease in All other segments. This reflects the strategic integration of VDI within Discovery Insure’s
international expansion and incentive-based behaviour programme, aligning the reporting structure with operational
responsibility and performance oversight.
19
-- 20 of 81 --
A.1 SEGMENT INFORMATION continued
R million Notes
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS
reporting
adjustments
IFRS
total
31 December 2025
Income statement
Insurance revenue 369 9 798 2 399 3 207 – 10 498 4 429 – 30 700 – 30 700
– Contracts measured under the General measurement model/Variable fee approach – 7 912 2 399 – – – 4 429 – 14 740 – 14 740
– Contracts measured under Premium allocation approach 369 1 886 – 3 207 – 10 498 – – 15 960 – 15 960
Insurance service expenses (260) (7 713) (1 570) (2 718) – (8 963) (3 845) 5 (25 064) – (25 064)
– Claims and benefits (184) (5 562) (342) (1 416) – (5 911) (1 824) 6 (15 233) – (15 233)
– Insurance service expense and other (45) (930) (742) (847) – (1 960) (334) (1) (4 859) – (4 859)
– Insurance acquisition cash flows (31) (1 221) (486) (455) – (1 092) (1 687) – (4 972) – (4 972)
Tax specific to policyholder tax funds1 – – (51) – – – – – (51) 51 –
Insurance service result (pre-reinsurance) 109 2 085 778 489 – 1 535 584 5 5 585 51 5 636
Net (expense)/income from reinsurance contracts (1) (525) – (58) – 3 (378) (2) (961) – (961)
– Reinsurance expense (1) (2 016) – (59) – (2) (4 650) – (6 728) – (6 728)
– Insurance claims recovered from reinsurers – 1 491 – 1 – 5 4 272 (2) 5 767 – 5 767
Insurance service result 108 1 560 778 431 – 1 538 206 3 4 624 51 4 675
Net financial result from insurance finance income and expense – 1 430 (14 072) (19) – – 118 – (12 543) 73 (12 470)
– Net finance income/(expense) from insurance contracts – 1 371 (14 072) (19) – – 315 – (12 405) 73 (12 332)
– Net finance expense from reinsurance contracts – 59 – – – – (197) – (138) – (138)
Investment income using the effective interest rate method 9 18 44 155 – 102 36 16 380 146 526
Net fair value gains on financial instruments at fair value through profit or loss – 2 958 14 870 – 33 28 – – 17 889 4 374 22 263
Fair value adjustments to liabilities under investment contracts2 – (2 678) (695) – – – – – (3 373) 35 (3 338)
Third-party interest: fair value adjustments to liabilities under investment contracts – – – – – – – – – (4 068) (4 068)
Net insurance and investment results 117 3 288 925 567 33 1 668 360 19 6 977 611 7 588
Fee income from administration businesses A.1.1 4 939 103 715 – – 19 – 1 300 7 076 (50) 7 026
Vitality income A.1.1 – – – – – 16 147 2 932 3 095 (293) 2 802
Net banking fee and commission income – – – – 848 – – (44) 804 186 990
– Banking fee and commission income – – – – 1 334 – – – 1 334 – 1 334
– Banking fee and commission expense – – – – (486) – – (44) (530) 186 (344)
Net banking interest and similar income – – – – 590 – – – 590 – 590
– Banking interest and similar income using the effective interest rate – – – – 1 243 – – – 1 243 – 1 243
– Banking interest and similar expense using the effective interest rate – – – – (653) – – – (653) – (653)
Other income A.1.1 960 93 – 31 25 – – 7 737 8 846 (7 825) 1 021
Non-insurance revenue and income 5 899 196 715 31 1 463 35 147 11 925 20 411 (7 982) 12 429
Net income 6 016 3 484 1 640 598 1 496 1 703 507 11 944 27 388 (7 371) 20 017
Non-insurance acquisition costs – – (257) – – – – (102) (359) 171 (188)
Expected credit losses – – – – (150) – – – (150) – (150)
Marketing and administration expenses A.1.2 (3 888) (391) (399) (112) (1 271) (517) (156) (11 985) (18 719) 7 627 (11 092)
Share of net profits from equity-accounted investments – – – 60 – – 1 670 731 (24) 707
Normalised profit/(loss) from operations A.2 2 128 3 093 984 546 75 1 186 352 527 8 891 403 9 294
Investment income earned on shareholder investments and cash 47 14 2 7 – – – 76 146 (146) –
Intercompany investment income – – – – – – – 706 706 (706) –
Net fair value gain on financial assets at fair value through profit or loss – 53 37 – – – – 35 125 (125) –
Amortisation of intangibles from business combinations – – – (24) – – – (39) (63) 63 –
Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – (25) (25) 25 –
Interest expenses on borrowings and lease liabilities (1) – – – – (9) (57) (736) (803) (134) (937)
Intercompany finance expenses on borrowings (233) – – – – – (237) (236) (706) 706 –
Foreign exchange (losses)/gains – – – – – – – (83) (83) – (83)
Profit/(loss) before income tax 1 941 3 160 1 023 529 75 1 177 58 225 8 188 86 8 274
Income tax expense3 (518) (853) (551) (138) (28) (295) (39) (7) (2 429) (86) (2 515)
Profit/(loss) for the period 1 423 2 307 472 391 47 882 19 218 5 759 – 5 759
Profit attributable to:
– Ordinary shareholders 1 424 2 307 472 391 47 882 19 174 5 716 – 5 716
– Preference shareholders – – – – – – – 44 44 – 44
– Non-controlling interest (1) – – – – – – – (1) – (1)
1 Tax specific to policyholder tax funds is reallocated from the income tax expense line. This includes taxes that are directly chargeable to the policyholder
under insurance contracts, with a corresponding change in the policyholder fund values, which are included within the insurance revenue line.
2 The value is reflected net of contract holder taxes, which are taxes directly chargeable to the contract holder. There is a corresponding change in the contract
holder value, which is included in the fair value measurement.
3 On consolidation, the allocations referred to in items 1 and 2 above are grossed up and presented within the income tax expense line, as required by IFRS
Accounting Standards. In addition, a deferred tax asset was recognised in prior years in respect of unutilised assessed losses accumulated within the
Individual Policyholder Fund (IPF), amounting to approximately R1.6bn (net). During the period under review, the deferred tax asset began to reverse as the
underlying assessed losses were utilised and, over the medium term, will result in an increase in reported income tax expense as the asset is utilised. This
increase is a non-cash item and does not give rise to current tax payable.
20 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 21
A. Notes to the Interim results continued
-- 21 of 81 --
A.1 SEGMENT INFORMATION continued
R million Notes
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS
reporting
adjustments
IFRS
total
31 December 2024 Restated1
Income statement
Insurance revenue 236 9 437 2 209 3 078 – 9 112 3 758 95 27 925 – 27 925
– Contracts measured under the General measurement model/Variable fee approach – 7 588 2 209 – – – 3 758 – 13 555 – 13 555
– Contracts measured under Premium allocation approach 236 1 849 – 3 078 – 9 112 – 95 14 370 – 14 370
Insurance service expenses (146) (7 525) (1 441) (2 690) – (8 280) (3 290) (111) (23 483) – (23 483)
– Claims and benefits (94) (5 788) (295) (1 568) – (5 367) (1 693) (74) (14 879) – (14 879)
– Insurance service expense and other (27) (678) (636) (672) – (1 957) (173) (33) (4 176) – (4 176)
– Insurance acquisition cash flows (25) (1 059) (510) (450) – (956) (1 424) (4) (4 428) – (4 428)
Tax specific to policyholder tax funds2 – – (46) – – – – – (46) 46 –
Insurance service result (pre-reinsurance) 90 1 912 722 388 – 832 468 (16) 4 396 46 4 442
Net expenses from reinsurance contracts (1) (580) – (52) – – (239) 6 (866) – (866)
– Reinsurance expense (1) (1 885) – (66) – (2) (4 270) (33) (6 257) – (6 257)
– Insurance claims recovered from reinsurers – 1 305 – 14 – 2 4 031 39 5 391 – 5 391
Insurance service result 89 1 332 722 336 – 832 229 (10) 3 530 46 3 576
Net financial result from insurance finance income and expense – 1 274 (7 454) – – – 145 – (6 035) (47) (6 082)
– Net finance income/(expense) from insurance contracts – 1 336 (7 454) – – – 273 – (5 845) (47) (5 892)
– Net finance expense from reinsurance contracts – (62) – – – – (128) – (190) – (190)
Investment income using the effective interest rate method 9 8 42 123 – 51 44 2 279 182 461
Net fair value (losses)/gains on financial instruments at fair value through profit or loss 6 1 584 8 216 8 (1) 60 – – 9 873 2 764 12 637
Fair value adjustments to liabilities under investment contracts3 – (1 317) (611) – – – – – (1 928) 9 (1 919)
Third-party interest: fair value adjustments to liabilities under investment contracts – – – – – – – – – (2 401) (2 401)
Other gains on financial instruments – – – – (9) – – – (9) – (9)
Net insurance and investment results 104 2 881 915 467 (10) 943 418 (8) 5 710 553 6 263
Fee income from administration businesses A.1.1 4 744 103 706 – – 17 – 1 527 7 097 (66) 7 031
Vitality income A.1.1 – – – – – 16 128 2 741 2 885 (267) 2 618
Net banking fee and commission income – – – – 611 – – (30) 581 150 731
– Banking fee and commission income – – – – 1 036 – – – 1 036 – 1 036
– Banking fee and commission expense – – – – (425) – – (30) (455) 150 (305)
Net banking interest and similar income – – – – 489 – – – 489 – 489
– Banking interest and similar income using the effective interest rate – – – – 1 105 – – – 1 105 – 1 105
– Banking interest and similar expense using the effective interest rate – – – – (616) – – – (616) – (616)
Other income A.1.1 882 50 – 44 21 10 – 7 133 8 140 (7 204) 936
Non-insurance revenue and income 5 626 153 706 44 1 121 43 128 11 371 19 192 (7 387) 11 805
Net income 5 730 3 034 1 621 511 1 111 986 546 11 363 24 902 (6 834) 18 068
Non-insurance acquisition costs – – (203) – – – – (114) (317) – (317)
Expected credit losses – – – – (118) – – – (118) – (118)
Marketing and administration expenses A.1.2 (3 707) (348) (446) (140) (1 138) (387) (221) (11 316) (17 703) 7 170 (10 533)
Share of net profits from equity-accounted investments – – – 36 – – 2 386 424 (25) 399
Normalised profit/(loss) from operations A.2 2 023 2 686 972 407 (145) 599 327 319 7 188 311 7 499
Investment income earned on shareholder investments and cash 43 14 5 – – – – 120 182 (182) –
Intercompany investment income – – – – – – – 681 681 (681) –
Net fair value gains/(losses) on financial assets at fair value through profit or loss – 41 35 – – – – 2 78 (78) –
Gain/(loss) from dilution and disposal of equity-accounted investments – – – (26) – – – – (26) – (26)
Amortisation of intangibles from business combinations – – – (25) – – – (29) (54) 54 –
Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – (44) (44) 44 –
Restructuring costs – – – – – – – (46) (46) 46 –
Interest expenses on borrowings and lease liabilities (1) – – – – (10) (104) (839) (954) (140) (1 094)
Intercompany finance expenses on borrowings (222) – – – – – (225) (234) (681) 681 –
Foreign exchange gains/(losses) (2) 3 (6) – – – – 18 13 – 13
Profit/(loss) before income tax 1 841 2 744 1 006 356 (145) 589 (2) (52) 6 337 55 6 392
Income tax expense (497) (735) (379) (103) 32 (147) (31) 15 (1 845) (55) (1 900)
Profit/(loss) for the year 1 344 2 009 627 253 (113) 442 (33) (37) 4 492 – 4 492
Profit attributable to:
– Ordinary shareholders 1 347 2 009 627 253 (113) 442 (33) (84) 4 448 – 4 448
– Preference shareholders – – – – – – – 47 47 – 47
– Non-controlling interest (3) – – – – – – – (3) – (3)
1 The comparative information has been restated due to (1) correction of a prior period error in line with and as disclosed in the annual financial statements
for the year ended 30 June 2025. Refer to D.1 for more details as well as (2) those changes
noted in items 1,2,3 and 4 as discussed in the introduction to Segment information in section A.1 "Changes effective from 1 July 2025".
2 Tax specific to policyholder tax funds is reallocated from the income tax expense line. This includes taxes that are directly chargeable to the policyholder
under insurance contracts, with a corresponding change in the policyholder fund values, which are included within the insurance revenue line.
3 The value is reflected net of contract holder taxes, which are taxes directly chargeable to the contract holder. There is a corresponding change in the contract
holder value, which is included in the fair value measurement.
22 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 23
A. Notes to the Interim results continued
-- 22 of 81 --
A.1 SEGMENT INFORMATION continued
A.1.1 Revenues and income with other operating segments
The net income presented within each respective segment includes the following items of revenue and income derived from
transactions with other operating segments of the Group:
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
31 December 2025
Fee income from administration businesses – – – – – – – 42 42
Vitality income – – – – – – – 293 293
Other income 124 86 – 23 25 48 – 7 735 8 041
Total 124 86 – 23 25 48 – 8 070 8 376
31 December 2024
Fee income from administration businesses – – – – – – – 60 60
Vitality income – – – – – – – 267 267
Other income1 116 49 – 12 21 – – 7 006 7 204
Total 116 49 – 12 21 – – 7 333 7 531
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the
annual financial statements for the year ended 30 June 2025. Refer to D.1 for more details.
A.1.2 Material items of expenses
Additional information on material items of expenses included within the marketing and administration expenses:
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
31 December 2025
Depreciation and amortisation (92) (1) (13) (1) (206) – (30) (640) (983)
Derecognition of intangible assets and property and equipment – – – (4) – – – (29) (33)
Staff costs (1 549) (196) (137) (39) (542) – – (4 311) (6 774)
Other expenses2 (2 247) (194) (249) (68) (523) (517) (126) (7 005) (10 929)
Total: Marketing and administration expenses (3 888) (391) (399) (112) (1 271) (517) (156) (11 985) (18 719)
31 December 2024
Depreciation and amortisation (74) – (9) (21) (191) – (28) (639) (962)
Derecognition of intangible assets and property and equipment – – – (4) – – – (21) (25)
Staff costs1 (1 440) (180) (124) (52) (483) – – (3 820) (6 099)
Other expenses1,2 (2 193) (168) (313) (63) (464) (387) (193) (6 836) (10 617)
Total: Marketing and administration expenses (3 707) (348) (446) (140) (1 138) (387) (221) (11 316) (17 703)
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the
annual financial statements for the year ended 30 June 2025. Refer to D.1 for more details.
2 Included in SA Health, other expenses are IT systems and consumables of R794 million (31 December 2024: R778 million).
24 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 25
A. Notes to the Interim results continued
-- 23 of 81 --
A.2 NORMALISED PROFIT FROM OPERATIONS
The following table shows the main components of the normalised profit from operations for the six months ended
31 December 2025:
R million
December
2025
Restated
December
20241
%
Change June 2025
Discovery Health 2 128 2 023 5% 4 259
Discovery Life 3 093 2 686 15% 5 525
Discovery Invest 984 972 1% 1 987
Discovery Insure 546 407 34% 817
Discovery Bank 75 (145) (152%) (68)
Other initiatives and central costs2 (51) (255) (80%) (515)
Normalised profit from Discovery SA 6 775 5 688 19% 12 005
VitalityHealth 1 186 599 98% 1 188
VitalityLife 352 327 8% 637
Ping An Health Insurance (PAHI)2 573 424 35% 1 206
Vitality Health International - Other2 (16) (149) (89%) (291)
Vitality Network2 176 339 (48%) 554
Vitality AI2,3 (155) (40) 288% (89)
Normalised profit from Vitality 2 116 1 500 41% 3 205
Normalised profit from operations 8 891 7 188 24% 15 210
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual
financial statements for the year ended 30 June 2025. Refer to D.1 for more details.
2 Presented in ‘All other segments’ in the Segment information disclosure note in section A.1.
3 Vitality AI also includes other central costs.
A.3 EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
December
2025
Restated
December
20241 June 2025
Number of shares used in calculation
Weighted number of shares in issue ('000) 669 610 663 795 665 168
Diluted weighted number of shares ('000) 672 737 667 131 668 715
Earnings per share (cents):
– basic 846.6 661.3 1 402.2
– diluted 842.7 658.0 1 394.9
Headline earnings per share (cents):
– basic 850.0 667.1 1 447.0
– diluted 846.1 663.7 1 439.4
Normalised headline earnings per share (cents):
– basic 858.0 679.6 1 470.4
– diluted 854.0 676.2 1 462.8
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES (‘000)
Issued ordinary shares at 1 July 666 587 661 021 661 021
Effect of share options exercised and vesting of share awards 3 023 2 774 4 147
Weighted-average number of ordinary shares (basic) 669 610 663 795 665 168
Effect of share options exercised and vesting of share awards 3 127 3 336 3 547
Weighted-average number of ordinary shares (diluted) 672 737 667 131 668 715
EARNINGS RECONCILIATION (R MILLION)
Profit attributable to the ordinary shareholders 5 716 4 448 9 471
Adjusted for:
– Profit attributable to non-forfeitable dividend share plan (47) (58) (144)
Basic earnings attributable to the ordinary shareholders 5 669 4 390 9 327
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual
financial statements for the year ended 30 June 2025. Refer to D.1 for more details.
26 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
A. Notes to the Interim results continued
-- 24 of 81 --
A.3 EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
continued
HEADLINE EARNINGS RECONCILIATION
Headline earnings per share is disclosed per the JSE Limited (JSE) Listings Requirements and is calculated in accordance with the
circular titled Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the
net profit after tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number
of ordinary shares in issue.
R million
December 2025
Restated
December
20241 June 2025
Gross Tax Net Gross Tax Net Gross Tax Net
Basic earnings attributable to the ordinary
shareholders 5 669 4 390 9 327
Adjusted for:
IFRS 3: Goodwill impairment – – – – – – 20 – 20
IFRS 5: Impairment - NCAHFS – – – – – – 79 – 79
IAS 16: Gain on disposal of property and
equipment (1) – (1) (1) – (1) (1) – (1)
IAS 16: Loss on derecognition of property and
equipment 5 (2) 3 4 (1) 3 11 (3) 8
IAS 16: Impairment of property and equipment – – – – – – 131 (19) 112
IAS 38: Loss on derecognition of intangible
assets 28 (7) 21 21 (5) 16 65 (10) 55
IAS 28: Loss/(gain) on the dilution and disposal
of equity-accounted investments – – – 26 (6) 20 32 (7) 25
Headline earnings (basic and diluted) 5 692 4 428 9 625
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual
financial statements for the year ended 30 June 2025. Refer to D.1 for more details.
NORMALISED HEADLINE EARNINGS RECONCILIATION
Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policies in note E.2. Management
considers that normalised headline earnings is an appropriate alternative performance measure to enhance the comparability
and understanding of the financial performance of the Group.
R million
December 2025
Restated
December
20241 June 2025
Gross Tax Net Gross Tax Net Gross Tax Net
Headline earnings 5 692 4 428 9 625
Adjusted for:
– Gain arising from the recognition of
deferred tax asset resulting from assessed
loss: Initial recognition – – – – – – – (9) (9)
– Amortisation of intangible assets arising
from business combinations 39 (10) 29 29 (7) 22 71 (18) 53
– Restructuring costs – – – 46 (10) 36 80 (19) 61
Adjustments attributable to equity-accounted
investments:
– Amortisation of intangible assets arising
from business combinations 24 – 24 25 – 25 51 – 51
Normalised headline earnings (basic
and diluted) 5 745 4 511 9 781
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual
financial statements for the year ended 30 June 2025. Refer to D.1 for more details.
27
-- 25 of 81 --
A.4 REVENUE FROM NON-INSURANCE ACTIVITIES
Discovery Group’s Revenue includes ‘Fee income from administration businesses’, ‘Vitality income’ and ‘Banking fee and
commission income’.
The split of revenue per geographical region and reportable segment can be viewed in Note A.1 Segment information.
The split of revenue according to the timing of satisfaction of performance obligations, i.e. ‘over time’ or a ‘point-in-time’
is as follows:
R million
December
2025
Restated
December
20241 June 2025
Fee income from administration businesses 7 026 7 031 14 326
– Over time 6 952 7 031 13 769
– Point-in-time2 74 – 557
Vitality income 2 802 2 618 5 322
– Over time 1 947 1 756 3 671
– Point-in-time 855 862 1 651
Banking fee and commission income 1 334 1 036 2 238
– Over time 460 361 1 455
– Point-in-time 874 675 783
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual
financial statements for the year ended 30 June 2025. Refer to D.1 for more details.
2 Included are specified contracts earning fee income from administration business through the Vitality Network. The variable consideration is estimated using
the expected value method, based on the present value of future expected fees from new business written by the customer. The resulting assets arising from
contracts with customers include inputs pertaining to foreign exchange rates as well as interest rates until such time as the value is settled in cash. During the
period under review, the JPY weakened significantly against the US$, and JPY government bond rates increased significantly. The impact of these losses
included within the remeasurement of revenue is US$6.8 million.
A.5 BORROWINGS AT AMORTISED COST
R million Reference
December
2025 June 2025
Borrowings from banks and listed debt 15 683 16 103
– UK borrowings A.5.1 1 166 3 710
– South African borrowings A.5.2 14 517 12 393
Bank overdraft in underlying liabilities of consolidated Unit Trusts – 2
Lease liabilities 3 796 3 941
– 1 Discovery Place (1 DP) 3 050 3 124
– Other lease liabilities 746 817
19 479 20 046
In October 2025, the Group settled £100 million of UK borrowings ahead of their contractual maturity in December 2025. The
settlement was funded through a drawdown of R1.5 billion under the Group’s existing revolving credit facility, together with additional
South African borrowings to fund the remaining balance. The refinancing was executed through an intercompany loan arrangement,
with the associated foreign exchange and interest rate exposures managed through a cross-currency basis swap.
A.5.1 UK borrowing facilities
Carrying amount
Facility
amount
GBP million Capital repayment and maturity date
December 2025 June 2025
Variable rate GBP R GBP R
25 SONIA + 275bps1 At Maturity - 23 December 2025 – – 25 608
75 SONIA + 300bps1 At Maturity - 21 December 2025 – – 75 1 828
55 SONIA + 285bps1 At Maturity - 11 December 20262 52 1 166 52 1 274
52 1 166 152 3 710
1 Interest payable quarterly in arrears.
2 The loan was extended from 12 December 2025 to 11 December 2026, during the current period.
Total finance costs in respect of the external UK borrowings for the six months ended 31 December 2025 were £4.02 million
(R93 million) (31 December 2024: £6.4 million (R148 million)).
A.5.2 South African borrowings
Credit rating
In January 2026 Moody’s Investors Service (“Moody’s”) affirmed Discovery Limited’s global scale long-term issuer rating of Ba3
and Aa3.za on the national scale. The outlook remained unchanged as stable, aligned to the outlook of the country.
28 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
A. Notes to the Interim results continued
-- 26 of 81 --
A.5 BORROWINGS AT AMORTISED COST continued
A.5.2 South African borrowings continued
DISCOVERY LIMITED
Carrying value
R million
Facility amount
R million Variable rate
Interest
per annum
Capital repayment
and maturity date
December
2025 June 2025
Listed DMTN
404 – 7.895% 1 At maturity – 21 November 2025 – 392
1111 3-month JIBAR + 95bps 7.73%2 At maturity – 21 May 2026 1 120 1 120
700 3-month JIBAR + 180bps 8.49% 2,3 At maturity – 21 August 2026 706 707
300 3-month JIBAR + 180bps 7.60% 2,3 At maturity – 21 August 2026 303 303
500 3-month JIBAR + 69bps 7.56%2 At maturity – 21 November 2026 504 –
792 3-month JIBAR + 173bps 7.98% 2,3 At maturity – 21 May 2027 799 799
576 3-month JIBAR + 140bps 7.50% 2,3 At maturity – 21 November 2027 581 581
750 3-month JIBAR + 140bps 7.19% 2,3 At maturity – 21 November 2027 757 758
226 3-month JIBAR + 180bps 7.98% 2,3 At maturity – 21 May 2029 228 228
924 3-month JIBAR + 159bps 8.17% 2,3 At maturity – 21 November 2029 932 932
1000 3-month JIBAR + 159bps 8.17% 2,3 At maturity – 21 November 2029 1 011 1 012
Unlisted DMTN4
1 650 – 9.55% 2 At maturity - 10 March 2026 1 659 1 659
Other
2 1005 3-month JIBAR + 115bps 7.93%2 At maturity - 18 August 2027 594 –
1 000 3-month JIBAR + 190bps 8.38% 3 At maturity – 02 March 2028 1 001 1 000
500 3-month JIBAR + 190bps 7.51% 3 At maturity - 02 March 2028 500 500
Total Discovery Limited Borrowings 10 695 9 991
1 Interest is payable semi-annually in arrears.
2 Interest payable quarterly in arrears.
3 The interest rate is the rate at which the 3-month JIBAR variable interest rate has been fixed.
4 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank-syndicated loans through the issue of unlisted DMTN notes.
The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market on an
ongoing basis.
5 The R2.1 billion Revolving Credit Facility was concluded on 19 August 2025. A commitment fee of 0.35% per annum is paid monthly in arrears on the
undrawn portion. R600 million of the facility was drawn down during October 2025.
DISCOVERY CENTRAL SERVICES
Carrying value
R million
Facility amount
R million
Interest rate
per annum
Capital repayment and
maturity date
December
2025 June 2025
1 500 3-month JIBAR + 130bps1 At maturity - 8 June 20262 1 507 –
691 3-month JIBAR + 190 bps1,3 At maturity - 30 June 2027 694 694
650 11.56% 4 At maturity - 29 October 2027 213 300
1 400 9.97% 4 At maturity - 20 December 2028 1 408 1 408
500 Prime rate less 145bps5 At maturity - 364-day notice – –
Total Discovery Central Services Borrowings 3 822 2 402
1 Interest payable quarterly in arrears.
2 During the year ended 30 June 2025, the maturity date of this Revolving Credit Facility was extended to 08 June 2026. The facility was drawn down during
October 2025.
3 The interest rate exposure has been capped at 8.36% through a derivative instrument.
4 Instalments of interest and capital are monthly.
5 The Revolving Credit Facility is a committed 364-day notice facility granted in November 2023. A commitment fee of 0.60% per annum is paid monthly in
arrears on the undrawn portion. This facility was not drawn down.
Total finance costs in respect of South African borrowings and related hedges for the six months ended 31 December 2025 were
R613 million (31 December 2024: R679 million).
29
-- 27 of 81 --
A.6 FAIR VALUE HIERARCHY
The Group’s assets and liabilities measured at fair value are disclosed in accordance with the fair value hierarchy. The hierarchy
has three levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes those assets and liabilities that are measured using unadjusted, quoted prices in an active market for identical
financial instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing
service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm’s length
basis.
Level 2: includes those assets and liabilities that are valued using techniques based significantly on observable market data.
Assets and liabilities in this category are valued using:
(a) Quoted prices for similar instruments or identical instruments in markets that are not considered to be active; or
(b) Valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3: includes those assets and liabilities that are valued using valuation techniques that incorporate information other than
observable market data and where at least one input (which could have a significant effect on the instruments’ valuation) cannot
be based on observable market data.
R million Level 1 Level 2 Level 3 Total
31 December 2025
Financial assets
Financial instruments mandatorily at fair value through
profit or loss: 161 600 55 266 2 216 868
– Equity portfolios 101 038 15 391 1 116 430
– Debt portfolios 60 562 2 203 – 62 765
– Money market portfolios – 9 949 – 9 949
– Multi-asset portfolios – 27 723 1 27 724
Derivative financial instruments at fair value: – 83 – 83
– used as cash flow hedges – – – –
– not designated as hedging instruments – 83 – 83
Total financial assets 161 600 55 349 2 216 951
Financial liabilities
Third-party interest in consolidated funds – 40 319 – 40 319
Investment contracts at fair value through profit or loss – 36 794 – 36 794
Derivative financial instruments at fair value: – 287 – 287
– used as cash flow hedges – 191 – 191
– not designated as hedging instruments – 96 – 96
Total financial liabilities – 77 400 – 77 400
There were no transfers between hierarchy levels during the current financial period.
30 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
A. Notes to the Interim results continued
-- 28 of 81 --
A.6 FAIR VALUE HIERARCHY continued
R million Level 1 Level 2 Level 3 Total
30 June 2025
Financial assets
Financial instruments mandatorily at fair value through
profit or loss: 141 140 52 636 – 193 776
– Equity portfolios 87 458 12 477 – 99 935
– Debt portfolios 53 682 2 186 – 55 868
– Money market portfolios – 12 948 – 12 948
– Multi-asset portfolios – 25 025 – 25 025
Financial instruments at fair value through other
comprehensive income: – – 14 14
– Equity portfolios – – 14 14
Derivative financial instruments at fair value: – 41 22 63
– used as cash flow hedges – 1 – 1
– not designated as hedging instruments – 40 22 62
Total financial assets 141 140 52 677 36 193 853
Non-financial assets
Non-current asset held for sale1 – – 62 62
Total assets 141 140 52 677 98 193 915
Financial liabilities
Third-party interest in consolidated funds – 35 932 – 35 932
Investment contracts at fair value through profit or loss – 32 188 – 32 188
Derivative financial instruments at fair value: – 135 – 135
– used as cash flow hedges – 117 – 117
– not designated as hedging instruments – 18 – 18
Total financial liabilities – 68 255 – 68 255
1 The fair value was determined from an agreed sales price between unrelated parties, reflecting an arm’s length transaction under current market conditions.
Given the agreed sales price, no variability is expected in the fair value measurement, as the transaction price represents the best available estimate of fair
value. The measurement approach incorporates relevant observable market inputs where available. The non-current asset held for sale was disposed of in
July 2025.
31
-- 29 of 81 --
A.6 FAIR VALUE HIERARCHY continued
Specific valuation techniques used to value financial instruments in level 2 and level 3
If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange-traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of
recent arm’s-length market transactions, reference to the current fair value of another instrument that is substantially the same,
discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices
obtained in actual market transactions.
Valuation techniques used in determining the fair value of assets and liabilities:
Instruments Valuation technique
Main inputs and
assumptions for level 2 and
level 3 fair value hierarchy
items
Within equity
portfolios, Equity-
linked notes
The calculation of the daily value of the equity-linked investments is
made by the provider of the note. Discovery has procedures in place
to ensure that these prices are correct. Aside from the daily
reasonableness checks versus similar funds and movement since the
prior day’s price, the fund values are calculated with reference to a
specific formula or index, disclosed to the policyholders, which is
recalculated by Discovery in order to check if the price provided by
the provider is correct.
■ discount rate
■ spot price of the underlying
Debt portfolios
and Money
market
instruments
Money market instruments are valued by discounting the future cash
flows using a risk-adjusted discount rate.
■ discount rate, credit spread
Multi-assets The fair values of financial liabilities arising on the consolidation of
mutual funds are determined using the quoted put (exit) price
provided by the fund manager and discounted for the applicable
notice period. The fair value of a financial liability with a demand
feature is not less than the amount payable on demand, discounted
from the first date on which the amount could be required to be paid.
■ discount rate
Investment
contracts at fair
value, including
third-party
interest in
consolidated
funds
Unit-linked policies: assets that are linked to the investment contract
liabilities are accounted for by the Group. The investment contract
obliges the Group to use these assets to settle these liabilities.
Therefore, the fair value of third-party interest in consolidated funds
and investment contract liabilities is determined with reference to the
fair value of the underlying assets (i.e., amount payable on surrender
of the policies).
Annuity: certain discounted cash flow models are used to determine
the fair value of the stream of future payments.
■ discount rate
■ spot price of the underlying
Derivatives Standard derivative contracts are valued using market-accepted
models and quoted parameter inputs. More complex derivative
contracts are modelled using more sophisticated modelling
techniques applicable to the instrument. Techniques include:
■ Discounted cash flow model
■ Black-Scholes model
■ Combination technique models
■ discount rate
■ spot price of the underlying
■ correlation factors
■ volatilities
■ earnings yield
■ valuation multiples
Unlisted equity
instruments at
fair value
For unlisted equity instruments, a discounted cash flow methodology
is used. The discounted cash flow methodology values an asset by
determining the present value of its expected future net cash flows.
This valuation considers both historic experience and future
projected budgets. The valuation is stress tested by considering
earnings multiples, e.g., price-earnings multiple (P/E ratio).
■ discount rate
■ growth rate
■ projected earnings
■ valuation multiples,
e.g., P/E ratio
32 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
A. Notes to the Interim results continued
-- 30 of 81 --
S E C T I O N B
Other significant items
in these results
34 B.1 Exchange rates to the South African rand
used in the preparation of these results
34 B.2 Capital management, financial leverage ratio
and covenants
36 B.3 Impact of financial risk variances within the
SA Life and UK Life operating segments
36 B.4 Cash and cash equivalents
37 B.5 Consolidation of Discovery Unit Trusts
37 B.6 Material transactions with related parties
37 B.7 Major customers and other Discovery
entities not part of Discovery Group
37 B.8 Changes in directorate
38 B.9 Events after reporting date
33
-- 31 of 81 --
B.1 EXCHANGE RATES TO THE SOUTH AFRICAN RAND USED IN THE PREPARATION OF
THESE RESULTS
Closing rates Average rates
Exchange rate to SA rand
December
2025
December
2024 June 2025
December
2025
December
2024 June 2025
US dollar 16.59 18.86 17.77 17.39 17.92 18.16
Pound sterling 22.27 23.61 24.34 23.29 23.14 23.48
Chinese yuan 2.37 2.53 2.48 2.44 2.50 2.51
B.2 CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS
The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the Group statement of
financial position. The Group’s objectives when managing capital are:
■ To comply with the statutory capital and liquidity requirements in each of its regulated entities;
■ To maintain a capital and liquidity buffer in excess of the statutory requirements in order to reduce the risk of breaching the
statutory requirements;
■ To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements;
■ To achieve an optimal and efficient capital funding profile; and
■ To consider capital management needs both in the short term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre
and subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across
the Group ultimately overseen by the Board.
A range of capital-raising options are available to manage the capital structure of the Group, which includes the issue of new
shares, debt, financial reinsurance arrangements and other hybrid instruments.
Regulatory capital
For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum
amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum
required capital must be maintained at all times throughout the period.
Discovery Life and Discovery Insure are regulated under the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential
Standards, while VitalityHealth and VitalityLife are regulated under the Solvency UK regulatory regime.
The table below summarises the capital requirements of insurance companies on a statutory basis, across the Group
subsidiaries, and the actual solvency capital held in relation to these requirements as at the end of the reporting period.
31 December 2025 31 December 2024
Statutory capital
requirements Cover
Statutory capital
requirements Cover
Discovery Life R27 801 million 1.8 times R24 228 million 1.8 times
Discovery Insure R1 201 million 2.1 times R1 141 million 2.0 times
VitalityHealth £121 million
R2 695 million 1.7 times
£118.9 million
R2 807 million 1.7 times
VitalityLife £421.5 million
R9 388 million 1.9 times
£368.8 million
R8 709 million 2.0 times
Discovery Bank’s common equity tier 1 (CET1) ratio is 14.91% (31 December 2024: 16.67%). In addition, the Bank holds an
internal management buffer to cater for future unexpected growth and volatility in risk weighted exposures, as well as an
estimation risk buffer.
34 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
B. Other significant items in these results
-- 32 of 81 --
B.2 CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS continued
As part of the capital management process, the Group monitors its capital structure in line with a Financial Leverage Ratio (FLR)
risk appetite. The Group’s strategy is to maintain a prudent FLR in line with Discovery’s risk appetite statement, with an overall
maximum FLR of 28%, which remains conservative.
The FLR is calculated as follows: total debt1 ÷ (total debt + total equity + 50% Contractual Service Margin (CSM) net of reinsurance
and net of tax). Non-recourse financial reinsurance and all IFRS 16 lease liabilities are not included in the measurement of total
debt.
R million
December
2025 June 2025
– Borrowings at amortised cost (refer to note A.5)1 15 683 16 105
Total debt1 15 683 16 105
Total equity 73 438 65 699
Total Contractual Service Margin (CSM)2 29 053 28 047
Financial leverage ratio % (50% CSM factored in) 15.1% 16.8%
1 Excludes all IFRS 16 lease liabilities of R3 796 million (30 June 2025: R3 941 million).
2 The CSM is net of reinsurance and net of tax.
The FLR at 31 December 2025 is within Discovery’s risk appetite.
Debt covenants
The following are the key debt covenant ratios and their proximity to minimum requirements as per the contractual financial
covenants.
Debt covenant and explanation Minimum requirement
December
2025 June 2025
Group Debt1 to EBITDA2 Ratio: Less than 2.5 times 0.90 times 1.02 times
Group financial indebtedness to embedded value3 Less than 30% of Group Embedded
value
12.1% 13.3%
Discovery Life Statutory Capital Requirement (SCR)
Cover
SCR cover must be more than 1.1 1.8 times 1.9 times
Group embedded value Greater than R30 billion R135 844
million
R126 554
million
New business embedded value must not be negative Positive value of new business for
3 consecutive 6-month periods
Dec 2025:
R1 356 million
Jun 2025:
R1 201 million
Dec 2024:
R953 million
Jun 2025:
R1 201 million
Dec 2024:
R953 million
Jun 2024:
R1 148 million
1 Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the 1 Discovery
Place (Discovery head office building in Sandton, South Africa) lease and includes guarantees issued to third parties.
2 EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1 Discovery Place and excludes items
deemed extraordinary and specified Financial Reinsurance (FinRe) arrangements.
3 Group financial indebtedness is as per Group Debt in the calculation.
35
-- 33 of 81 --
B.3 IMPACT OF FINANCIAL RISK VARIANCES WITHIN THE SA LIFE AND UK LIFE
OPERATING SEGMENTS
The actuarial bases of Discovery Life and VitalityLife are actively maintained to ensure that the most up-to-date view of best-
estimate expectations of the future is accurately reflected.
In accordance with IFRS 17, financial risk assumptions are updated to reflect current market prices as at the reporting date.
Discovery has elected, as permitted under IFRS 17 Insurance Contracts, to recognise the impact of changes in these assumptions
at the end of the reporting period within Other Comprehensive Income (OCI) for the specified portfolios. Consequently, changes
in financial risk, including changes in the discount rate, do not directly affect the Group income statement due to this election.
Instead, the effect of changes in financial risk during the period is recognised within net finance income and expenses from
insurance contracts issued and reinsurance contracts held in OCI, with the cumulative effect presented in the Insurance Finance
Reserve within equity.
During the six-month period ended 31 December 2025, a significant reduction in government bond yield curves in South Africa
(c.275 bps in weighted average nominal rate, c.100 bps reduction in weighted average real rate) resulted in gains recognised in
OCI, thereby improving the Insurance Finance Reserve for Discovery Life.
The balance of the Insurance Finance Reserve will effectively be reclassified to profit or loss using a systematic rate over the
remaining life of each relevant group of contracts. The systematic rate is determined such that, over the lifetime of the contracts,
the Insurance Finance Reserve reverts to zero.
A summary of the movements in the Insurance Finance Reserve, net of reinsurance and net of tax, for the respective portfolios
during the period is set out below.
Insurance Finance Reserve
Accumulated (income)/expense
R million
SA Life Risk
(GMM)
SA Life:
Group Life and
Other (PAA)
UK Life Risk
(GMM) Total
Balance at beginning of the period 5 938 (262) (2 748) 2 928
Net finance (income)/expense recognised in other
comprehensive income for the period (5 553) 137 (452) (5 868)
Balance at end of the period 385 (125) (3 200) (2 940)
B.4 CASH AND CASH EQUIVALENTS
B.4.1 Group Statement of Cash Flows
R million Reference
December
2025
31 December
2024
Cash flows from operating activities i 1 965 3 546
Cash flows from investing activities (812) (1 304)
Cash flows from financing activities (1 765) (1 938)
Net (decrease)/increase in cash and cash equivalents (612) 304
(i) Discovery’s cash flows from operating activities for the six months ended 31 December 2025 totalled R1 965 million
(31 December 2024: R3 546 million).
Organic cash generation was driven by the favourable underwriting experience across insurance entities and positive
contributions from Discovery Health and Discovery Vitality. The key factors that offset the positive cashflows are:
■ Higher loans and advances coupled with lower deposits in Discovery Bank for the six months ended 31 December 2025
resulted in cash utilised of an additional R1 611 million compared to the prior period.
■ In the prior period, additional Value-in-Force (VIF) monetisation by means of financial reinsurance in VitalityLife increased
operational cash flow by R1 157 million. This additional cash flow was used to cover operational needs as well as to ensure
cash remained above the liquidity risk appetite.
■ Taxation paid increased by R579 million compared to the prior period, reflecting higher cash tax payable following the
utilisation of assessed losses and tax credits in the prior period.
The Group statement of cash flows includes cash flows relating to policyholders as well as those arising from the consolidated
Discovery Unit Trusts and therefore to assist in the understanding of cash flows not distorted by policyholder flows, a Group
shareholder free cash movement has been included in additional analyst information published on Discovery’s website.
36 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
B. Other significant items in these results continued
-- 34 of 81 --
B.4 CASH AND CASH EQUIVALENTS continued
B.4.2 Shareholder cash and cash equivalents
R million Shareholder
Unit-linked
investment
and insurance
contracts1 Total
31 December 2025
Cash and cash equivalents at beginning of the period 17 216 4 750 21 966
Effects of exchange rate changes on cash and cash equivalents (587) – (587)
Decrease in cash and cash equivalents (365) (247) (612)
Cash and cash equivalents at end of the period 16 264 4 503 20 767
1 Includes cash held within specific portfolios to match specific insurance liabilities.
Included in shareholder cash, is the cash held in the Group’s insurance entities which is used to fund new business and match
claims and other policyholder-related liabilities. This cash, together with the cash balances held by Discovery Bank of R4.9 billion
(30 June 2025: R6.3 billion), although unencumbered, is held for specific purposes and therefore not considered available for
distribution.
Cash available to support Group liquidity requirements is R2.5 billion (30 June 2025: R2.6 billion). In addition, the Group also has
undrawn revolving credit facilities of R2 billion at 31 December 2025.
B.5 CONSOLIDATION OF DISCOVERY UNIT TRUSTS
Unit trusts that the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results
for accounting purposes, which results in the recognition of the underlying assets and liabilities of each of the funds.
As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders.
Assets and liabilities of these Discovery Unit Trusts however increased by R3 916 million, compared to the prior financial year
ended 30 June 2025, with movements in the following line items on the Group’s statement of financial position:
R million
December
2025
Restated
June 20251 Movements
Investments at fair value through profit or loss 37 071 32 513 4 558
Contract receivables and other receivables 803 1 214 (411)
Cash and cash equivalents 2 671 2 910 (239)
Other assets 19 11 8
Total change in assets 40 564 36 648 3 916
Third-party interest in consolidated funds 40 319 35 932 4 387
Borrowings at amortised costs (bank overdraft) – 2 (2)
Other payables and provisions 194 626 (432)
Liabilities arising from insurance contracts issued – 73 (73)
Other liabilities 51 15 36
Total change in liabilities 40 564 36 648 3 916
1 The comparatives have been restated to reflect the impact of consolidating the global multi-asset investment funds managed through Discovery Mauritius
Asset Management, in line with the presentation of the impact in the current reporting period.
There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The net cash inflow of the movement in
policyholder investments for the period is R280 million and has been included in the ‘Increase in operating assets’ line item on
the Group’s statement of cash flows.
B.6 MATERIAL TRANSACTIONS WITH RELATED PARTIES
The nature of the related party transactions of the Group has not changed significantly from those described in the consolidated
financial statements for the year ended 30 June 2025.
B.7 MAJOR CUSTOMERS AND OTHER DISCOVERY ENTITIES NOT PART OF DISCOVERY
GROUP
Discovery Health Medical Scheme (DHMS)
Discovery Health administers DHMS and provides managed care services, for which it charges an administration fee and a
managed healthcare fee, respectively. These fees are determined on an annual basis and approved by the trustees of DHMS.
The fees totalled R4 131 million for the period ended 31 December 2025 (31 December 2024: R4 063 million). Discovery offers
the members of DHMS access to the Vitality programme.
B.8 CHANGES IN DIRECTORATE
Changes to the Board of Discovery Limited from 1 July 2025 to the date of this announcement are as follows:
■ Ms VN Fakude has been appointed as an independent non-executive director with effect from 1 September 2025.
She is a member of the Discovery Limited Nominations, Remuneration and Social and Ethics Committees. Her appointment will
further augment the Board’s global business experience and expertise while improving its diversity.
37
-- 35 of 81 --
B.9 EVENTS AFTER REPORTING DATE
The following non-adjusting events occurred between the end of the reporting period and the date when the financial results
were authorised for issue.
B.9.1 Dividend declaration in respect of the six months ended 31 December 2025
B Preference share cash dividend declaration
On Thursday, 26 February 2026, the Board of directors declared an interim gross cash dividend of 528.76712 cents (423.01370
cents net of dividend withholding tax) per B preference share for the period 1 July 2025 to 31 December 2025, payable from the
income reserves of the Company.
A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares. The salient dates for the dividend
will be as follows:
Last day of trade to receive a dividend Tuesday, 17 March 2026
Shares commence trading “ex” dividend Wednesday, 18 March 2026
Record date Friday, 20 March 2026
Payment date Monday, 23 March 2026
B preference share certificates may not be dematerialised or rematerialised between Wednesday, 18 March 2026 and
Friday, 20 March 2026, both days inclusive.
Ordinary share cash dividend declaration
On Monday 2 March 2026 the Board of Directors declared an interim gross cash dividend of 111.00000 cents (88.80000 cents net
of dividend withholding tax) per ordinary share, out of the income reserves of the company. A dividend withholding tax of 20%
will be applicable to all shareholders who are not exempt.
The number of ordinary shares in issue at the date of declaration is 682 491 619.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend Monday, 30 March 2026
Shares commence trading “ex” dividend Tuesday, 31 March 2026
Record date Thursday, 2 April 2026
Payment date Tuesday, 7 April 2026
Ordinary share certificates may not be dematerialised or rematerialised between Tuesday, 31 March 2026 and Thursday,
2 April 2026, both days inclusive.
B.9.2 Purchase of Discovery’s Head Office Building, 1 Discovery Place (1DP)
As announced on SENS on 6 February 2026, the Group intends to acquire Phase 1 ("Grove and Park buildings") of 1DP and cancel
the lease for Phase 2 ("Ridge building"). This will be facilitated through Discovery Propco (Pty) Limited, a wholly owned subsidiary
of Discovery. The total consideration of the transaction is R4.05 billion (exclusive of VAT), and the acquisition will be fully funded
through pre-arranged debt.
As at the date of these results, the transaction remains subject to Competition Authority approval and other customary
suspensive conditions. Accordingly, the timing of completion may extend into the next financial year.
Once effective, the transaction will result in:
■ Derecognition of the right-of-use assets and lease liabilities relating to 1 Discovery Place (Phases 1 and 2), with a net gain of
between c.R1.3 billion - c.R1.6 billion pre-tax. The net gain attributable to Phase 1 acquisition would be excluded from
normalised profit from operations as well as normalised headline earnings.
■ Recognition of the acquired land and buildings, together with external borrowings.
■ An initial increase in the FLR, followed by a continued reduction towards the lower end of the Group's guidance range of 10%
to 20% over the next few years.
38 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
B. Other significant items in these results continued
-- 36 of 81 --
S E C T I O N C
Insurance and
reinsurance contracts
related disclosure
40 C.1.1 Insurance and reinsurance contracts
disclosures and reconciliations
44 C.1.2.1 Summary of insurance contracts issued and
reinsurance contracts held
45 C.1.2.2 Summary of movements
48 C.1.2.3 Movement in insurance contract balances:
GMM
54 C.1.2.4 Movement in insurance contract balances:
VFA
56 C.1.2.5 Movement in reinsurance contract balances:
GMM
60 C.1.2.6 Insurance revenue
62 C.1.2.7 Net investment result
66 C.1.2.8 Effect of contracts initially recognised in the
period
39
-- 37 of 81 --
C.1.1 INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS
The following disclosures enable the user to assess the effect of insurance contracts issued and reinsurance contracts held on
Discovery’s financial position, financial performance and cash flows.
Introduction
To assist the users of the financial statements in understanding the insurance and reinsurance disclosures, Section C disclosures
have been re-presented in line with and as disclosed in the annual financial statements for the year ended 30 June 2025, for the
following:
1. The Discovery SA Life and Invest (Risk) (GMM) portfolio has been split into two separate portfolios —SA Life (Risk) (GMM) and
SA Invest (Risk) (GMM). This change is purely a re-presentation of the information, with no impact on the total values
reported in the SA Life and SA Invest disclosures.
The purpose of this split is to provide users of the financial statements with a clearer view of the movements within each
portfolio during the reporting period. By presenting SA Life (Risk) (GMM) and SA Invest (Risk) (GMM) separately, the users of
the financial statements can better understand the distinct performance and financial impact of each portfolio during the
reporting period.
2. The net investment note has been updated to provide a granular breakdown of the key components driving the interest
accretion as presented in profit or loss and OCI. The change is aimed at providing the users of the financial statements a
better understanding of the detailed interest accretion components.
3. The comparative disclosures for the Discovery SA Life (Risk) (GMM) portfolio have been restated due to a correction of a
prior period error in line with and as disclosed in the annual financial statements for the year ended 30 June 2025, refer to
section D.1 for more detail. Refer to the index summary table for all the notes that have been restated.
IFRS 17 requires that in determining the level at which an aggregated group of insurance contracts can provide useful
information to the user, Discovery considers:
■ The type of contract that would consider the nature of the product and the measurement model.
■ The geographical areas that may expose the entity to different sets of risks, even for similar products.
■ Reportable segments.
Having applied the guidance, Discovery has aggregated its portfolios for the disclosures as set out below.
40 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
C. Insurance and reinsurance contracts related disclosure
SA Life (Risk) | GMM
(Individual Life, Dollar LifePlan,
Health Protection Plans, Standalone Global Educator)
SA Invest (Risk) | GMM
(Guaranteed endowments)
SA Invest (Participating) | VFA
(Unit-linked invest products, Unit-linked insurance
products and Discovery Retirement Optimiser)
SA Life and Invest: Group Life and other | PAA
(Group Risk, Funeral and other including Discovery Card
Protector, Standalone Cancer Protector and LifeDrive)
SA Insure and other | PAA
(Personal and Commercial lines, GAP and Trauma Cover,
Travel Cover and AfricaHealth)
UK Life (Risk) | GMM
(Own Licence and PAC book)
UK Health | PAA
(Private Medical Insurance)
-- 38 of 81 --
C.1.1 INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS continued
The following index is a summary of all the quantitative disclosures set out in the notes:
Note Description
Analysis of
financial
position
C.1.2.1 Summary of insurance contracts issued
and reinsurance contracts held1,2
Summary of movements
C.1.2.2.1 Contractual service margin
C.1.2.2.2 Insurance Finance Reserve
The note summarises the total value of insurance and
reinsurance contracts held as well as a summary of
movements in the CSM and IFR, across the disclosed
portfolios. Insurance and reinsurance contracts are
presented separately for portfolios in a net liability or net
asset position.
Reconciliation of insurance contracts
Analysis by measurement component
GMM
C.1.2.3.1 SA Life (Risk)1,2
C.1.2.3.2 SA Invest (Risk)1,2
C.1.2.3.3 UK Life (Risk)
VFA
C.1.2.4.1 SA Invest (Participating)
Reconciliation of reinsurance contracts
Analysis by measurement component
GMM
C.1.2.5.1 SA Life (Risk)2
C.1.2.5.2 UK Life (Risk)
The notes provide a detailed reconciliation of disclosed
portfolios showing the build-up of the measurement
components, namely:
■ Estimates of the present value of expected fulfilment
cash flows.
■ The Risk adjustment.
■ The Contractual service margin reflects unearned
profit. The CSM is further separated to reflect how the
CSM was calculated at transition, being modified
retrospectively or fully retrospectively.
1 The comparative information for December 2024 has been restated for the correction of the prior period errors in line with and as disclosed in the annual
financial statements for the year ended 30 June 2025. Refer to D.1 Refer to item 3 noted in the introduction of section C.
2 The note has been re-presented for the split of the Discovery SA Life and Invest (Risk) (GMM) portfolio. Refer to item 1 noted in the introduction of section C.
41
-- 39 of 81 --
C.1.1 INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS continued
Note Description
Analysis of
income
statement
C.1.2.6 Insurance revenue1,2 The note provides a breakdown of the makeup of
insurance revenue for each disclosed portfolio business
unit.
For those contracts not measured using the PAA
approach, the amount reflects the provision of services
and the recovery of insurance acquisition cash flows. The
provision of services is represented by the change in the
LRC, namely:
■ CSM recognised during the period for the service
provided.
■ The change in the risk adjustment for non-financial
risk.
■ Expected claims and insurance services expenses.
■ Experience adjustments.
C.1.2.7 Net investment result1,2,3 The note provides a holistic view of the following:
■ The investment returns on financial assets held.
■ The insurance and reinsurance finance income and
expenses, including the amounts recognised in profit
or loss and other comprehensive income (OCI).
Additional
information
Effect of contracts initially recognised in the
period:
C.1.2.8 Effect of insurance contracts initially
recognised in the period2.
C.1.2.8 Effect of reinsurance contracts initially
recognised in the period2.
The notes provide a breakdown of the contracts initially
recognised during the period for each disclosed portfolio
business unit.
■ For insurance contracts, differentiate between
profitable contracts recognised with CSM and onerous
contracts.
■ Reinsurance contracts reflect contracts originated with
and without the loss-recovery component.
1 The comparative information has been restated due to correction of a prior period error. Refer to item 3 noted in the introduction of section C.
2 The note has been re-presented for the split of the Discovery SA Life and Invest (Risk) (GMM) portfolio. Refer to item 1 noted in the introduction of section C.
3 The note has been re-presented to provide a granular breakdown of interest accretion components. Refer to item 2 noted in the introduction of section C.
42 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
C. Insurance and reinsurance contracts related disclosure continued
-- 40 of 81 --
C.1.1 INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS continued
Definitions and Abbreviations
The following abbreviations and terms are commonly used within the IFRS 17 disclosures:
Abbreviation or
definition Meaning
CSM Contractual Service Margin
DISCOVERY Discovery Group
DPF Direct Participation Features
DRO Discovery Retirement Optimiser
EFCF Expected Fulfilment Cash Flows
FINANCIAL RISK The risk of a possible future change in one or more of a specified interest rate, financial instrument
price, commodity price, currency exchange rate, index of prices or rates, credit rating or credit index
or other variable, provided in the case of a non-financial variable that the variable is not specific to a
party to the contract.
GMM General Measurement Model
IACF Insurance Acquisition Cash Flows
IFIE Insurance finance income and expense comprise of the change in the carrying amount of the group
of insurance contracts arising from:
■ The effect of the time value of money and changes in the time value of money, and
■ The effect of financial risk and changes in financial risk
IFR Insurance Finance Reserve
IFRS IFRS® Accounting Standards
IFRS 17 IFRS 17 Insurance Contracts (effective for Discovery post 1 July 2023)
IFRS 17 margins IFRS 17 margins refer to the contractual service margin plus the risk adjustment
ISE Insurance Service Expenses
LIC Liability for Incurred Claims
LRC Liability for Remaining Coverage
OCI Other Comprehensive Income
PAA Premium Allocation Approach
VFA Variable Fee Approach
43
-- 41 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.1 Summary of insurance contracts issued and reinsurance contracts held
Group
R million (Assets)/Liabilities Navigation
SA
Life
Risk
(GMM)
SA
Invest
Risk
(GMM)
UK Life
Risk
(GMM)
SA
Invest
Partici-
pating
(VFA)
SA Life:
Group
Life and
other
(PAA)
SA Insure
and other
(PAA)
UK
Health
(PAA) Total
Six months ended
31 December 2025
Insurance Contracts A = D + E (32 903) 24 726 (20 479) 100 719 6 819 831 (4 859) 74 854
Reinsurance Contracts B = F 762 – 9 592 – (933) (32) (13) 9 376
Total C = A +B (32 141) 24 726 (10 887) 100 719 5 886 799 (4 872) 84 230
Insurance contracts issued
Assets arising from
insurance contracts
– Insurance contract
balances (32 903) – (20 479) – – – 691 (52 691)
– Assets for insurance
acquisition cash flows – – – – – – (5 550) (5 550)
Total D (32 903) – (20 479) – – – (4 859) (58 241)
Liabilities arising from
insurance contracts
– Insurance contract
balances – 24 726 – 100 719 6 819 831 – 133 095
Total E – 24 726 – 100 719 6 819 831 – 133 095
Reinsurance contracts held
Reinsurance contract assets – – – – (933) (32) (13) (978)
liabilities 762 – 9 592 – – – – 10 354
Total F 762 – 9 592 – (933) (32) (13) 9 376
Year ended
30 June 2025
Insurance Contracts (23 002) 23 580 (20 180) 88 150 6 414 734 (4 865) 70 831
Reinsurance Contracts 370 – 8 751 – (865) (84) (13) 8 159
Total (22 632) 23 580 (11 429) 88 150 5 549 650 (4 878) 78 990
Insurance contracts issued
Assets arising from
insurance contracts
– Insurance contract
balances (23 002) – (20 180) – – – 884 (42 298)
– Assets for insurance
acquisition cash flows – – – – – – (5 749) (5 749)
Total (23 002) – (20 180) – – – (4 865) (48 047)
Liabilities arising from
insurance contracts
– Insurance contract
balances – 23 580 – 88 150 6 414 734 – 118 878
– 23 580 – 88 150 6 414 734 – 118 878
Reinsurance contracts held
Reinsurance contract assets – – – – (865) (84) (13) (962)
Reinsurance contract
liabilities 370 – 8 751 – – – – 9 121
Total 370 – 8 751 – (865) (84) (13) 8 159
Cross reference to related
notes of insurance contracts
issued
– Analysis by measurement
component C.1.2.3.1 C.1.2.3.2 C.1.2.3.3 C.1.2.4.1
Cross reference to related
notes of reinsurance
contracts held
– Analysis by measurement
component C.1.2.5.1 C.1.2.5.2
44 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
C. Insurance and reinsurance contracts related disclosure continued
-- 42 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.2 Summary of movements
C.1.2.2.1 CONTRACTUAL SERVICE MARGIN (CSM)
ANALYSIS OF INSURANCE CONTRACT CSM
Group
R million (Assets)/Liabilities
SA
Life Risk
(GMM)
SA
Invest
Risk
(GMM)
UK Life
Risk (GMM)
SA Invest
Partici-
pating
(VFA) Total
Six months ended 31 December 2025
Balance at beginning of the period 27 295 820 15 349 7 108 50 572
Changes that relate to current services
CSM recognised for services provided (1 052) (166) (715) (718) (2 651)
Experience adjustments – – – 8 8
Changes that relate to future services
Contracts initially recognised in the period 846 86 1 351 270 2 553
Changes in estimates that adjust CSM (237) 42 89 995 889
Net finance expenses from insurance contracts 1 244 37 164 527 1 972
Effects of movement in exchange rates – – (1 345) – (1 345)
Net changes 801 (1) (456) 1 082 1 426
Balance at the end of the period 28 096 819 14 893 8 190 51 998
Year ended 30 June 2025
Balance at beginning of the period 28 842 941 13 311 6 306 49 400
Changes that relate to current services
CSM recognised for services provided (1 862) (395) (1 332) (1 324) (4 913)
Experience adjustments – – – 34 34
Changes that relate to future services
Contracts initially recognised in the period 1 286 245 2 128 732 4 391
Changes in estimates that adjust CSM (3 684) (66) 166 258 (3 326)
Net finance expenses from insurance contracts 2 713 95 298 1 102 4 208
Effects of movement in exchange rates – – 778 – 778
Net changes (1 547) (121) 2 038 802 1 172
Balance at the end of the period 27 295 820 15 349 7 108 50 572
45
-- 43 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.2 Summary of movements continued
C.1.2.2.1 CONTRACTUAL SERVICE MARGIN (CSM) continued
ANALYSIS OF REINSURANCE CONTRACT CSM
Group
R million (Assets)/Liabilities
SA
Life Risk
(GMM)
SA
Invest
Risk
(GMM)
UK Life
Risk
(GMM)
SA Invest
Partici-
pating
(VFA) Total
Six months ended 31 December 2025
Balance at beginning of the period (4 608) – (7 751) – (12 359)
Changes that relate to current services
CSM recognised for services provided 164 – 360 – 524
Changes that relate to future services
Contracts initially recognised in the period (113) – (881) – (994)
Changes in estimates that adjust CSM (54) – 109 – 55
Net finance expenses from reinsurance contracts (200) – (106) – (306)
Effects of movement in exchange rates – – 683 – 683
Net changes (203) – 165 – (38)
Balance at the end of the period (4 811) – (7 586) – (12 397)
Year ended 30 June 2025
Balance at beginning of the period (5 070) – (5 719) – (10 789)
Changes that relate to current services
CSM recognised for services provided 325 – 636 – 961
Changes that relate to future services
Contracts initially recognised in the period (172) – (1 782) – (1 954)
Changes in estimates that adjust CSM 842 – (331) – 511
Net finance expenses from reinsurance contracts (533) – (180) – (713)
Effects of movement in exchange rates – – (375) – (375)
Net changes 462 – (2 032) – (1 570)
Balance at the end of the period (4 608) – (7 751) – (12 359)
46 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
C. Insurance and reinsurance contracts related disclosure continued
-- 44 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.2 Summary of movements continued
C.1.2.2.2 INSURANCE FINANCE RESERVE
Group
R million Accumulated (income)/ expense
SA
Life Risk (GMM)
SA Life: Group
Life and other
(PAA)
UK Life
Risk
(GMM) Total
Six months ended 31 December 2025
Balance at beginning of the period 5 938 (262) (2 748) 2 928
Net finance (income)/ expense for insurance contracts
Amounts recognised in OCI (8 280) 215 (681) (8 746)
Related tax effects 2 236 (58) 170 2 348
Net finance income/ (expense) for reinsurance contracts
Amounts recognised in OCI 673 (27) 78 724
Related tax effects (182) 7 (19) (194)
Balance at the end of the period 385 (125) (3 200) (2 940)
Year ended 30 June 2025
Balance at beginning of the period 7 003 (214) (1 957) 4 832
Net finance (income)/ expense for insurance contracts
Amounts recognised in OCI (1 684) (74) (1 203) (2 961)
Related tax effects 455 20 300 775
Net finance income/ (expense) for reinsurance contracts
Amounts recognised in OCI 221 8 153 382
Related tax effects (57) (2) (41) (100)
Balance at the end of the period 5 938 (262) (2 748) 2 928
47
-- 45 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.3 Movement in insurance contract balances: GMM
C.1.2.3.1 SA Life (risk)
ANALYSIS BY MEASUREMENT COMPONENT
December 2025 June 2025
Group
R million (Assets)/Liabilities
RA for non-
financial
Risk
CSM
RA for non–
financial
Risk
CSM
Navigation
Estimates of
PVFCF
Other
contracts Total
Estimates of
PVFCF Other contracts Total
Opening assets arising from insurance
contracts issued (58 654) 8 357 27 295 (23 002) (54 499) 7 811 28 842 (17 846)
Net balance at beginning of the
period A (58 654) 8 357 27 295 (23 002) (54 499) 7 811 28 842 (17 846)
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided – – (1 052) (1 052) – – (1 862) (1 862)
Change in Risk Adjustment for
non-financial risk that
relates to expired risk – (311) – (311) – (642) – (642)
Experience adjustments (364) – – (364) (724) – – (724)
Changes that relate to future services
Contracts initially recognised in the
period (1 051) 229 846 24 (1 647) 395 1 286 34
Changes in estimates that adjust CSM 469 (232) (237) – 4 046 (362) (3 684) –
Changes in estimates that result in
onerous contract
losses or reversal of losses 363 (23) – 340 202 (14) – 188
Servicing expenses and commission for
onerous contracts 8 – – 8 13 – – 13
Changes that relate to past services
Adjustment to liability for incurred
claims – (1) – (1) – 6 – 6
Insurance service result B (575) (338) (443) (1 356) 1 890 (617) (4 260) (2 987)
Net finance expenses from insurance
contracts C (14 210) 3 086 1 244 (9 880) (8 647) 1 163 2 713 (4 771)
Net changes to income statement
and OCI D = B + C (14 785) 2 748 801 (11 236) (6 757) 546 (1 547) (7 758)
Cash flows E 1 335 – – 1 335 2 602 – – 2 602
Net balance at the end of the period G = A + D + E (72 104) 11 105 28 096 (32 903) (58 654) 8 357 27 295 (23 002)
Closing assets arising from insurance
contracts issued (72 104) 11 105 28 096 (32 903) (58 654) 8 357 27 295 (23 002)
Net balance at the end of the period (72 104) 11 105 28 096 (32 903) (58 654) 8 357 27 295 (23 002)
48 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 49
C. Insurance and reinsurance contracts related disclosure continued
-- 46 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.3 Movement in insurance contract balances: GMM continued
C.1.2.3.2 SA Invest (risk)
ANALYSIS BY MEASUREMENT COMPONENT
December 2025 June 2025
Group
R million (Assets)/Liabilities
RA for non-
financial
Risk
CSM
RA for non
- financial
Risk
CSM
Navigation
Estimates of
PVFCF
Other
contracts Total
Estimates of
PVFCF
Other
contracts Total
Opening liabilities arising from
insurance contracts issued 22 570 190 820 23 580 23 489 135 941 24 565
Net balance at beginning of the
period A 22 570 190 820 23 580 23 489 135 941 24 565
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided – – (166) (166) – – (395) (395)
Change in Risk Adjustment for non-
financial risk that relates to expired risk – (26) – (26) – (38) – (38)
Experience adjustments 3 – – 3 32 – – 32
Changes that relate to future services
Contracts initially recognised in the
period (93) 11 86 4 (266) 25 245 4
Changes in estimates that adjust CSM 1 (43) 42 – 49 17 (66) –
Changes in estimates that result in
onerous contract losses or reversal of
losses (7) (51) – (58) (5) 23 – 18
Changes that relate to past services
Adjustment to liability for incurred
claims – – – – – – – –
Insurance service result B (96) (109) (38) (243) (190) 27 (216) (379)
Net finance expenses from insurance
contracts C 2 567 41 37 2 645 2 805 28 95 2 928
Net changes to income statement
and OCI D = B + C 2 471 (68) (1) 2 402 2 615 55 (121) 2 549
Cash flows E (1 256) – – (1 256) (3 534) – – (3 534)
Net balance at the end of the period G = A + D + E 23 785 122 819 24 726 22 570 190 820 23 580
Closing liabilities arising from insurance
contracts issued 23 785 122 819 24 726 22 570 190 820 23 580
Net balance at the end of the period 23 785 122 819 24 726 22 570 190 820 23 580
50 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 51
C. Insurance and reinsurance contracts related disclosure continued
-- 47 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.3 Movement in insurance contract balances: GMM continued
C.1.2.3.3 UK Life (risk)
ANALYSIS BY MEASUREMENT COMPONENT
December 2025 June 2025
Group
R million (Assets)/Liabilities
RA for non-
financial
Risk
CSM
RA for non-
financial
Risk
CSM
Navigation
Estimates of
PVFCF
Other
contracts Total
Estimates of
PVFCF
Other
contracts Total
Opening assets arising from insurance
contracts issued (38 091) 2 562 15 349 (20 180) (30 819) 2 239 13 311 (15 269)
Net balance at beginning of the
period A (38 091) 2 562 15 349 (20 180) (30 819) 2 239 13 311 (15 269)
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided – – (715) (715) – – (1 332) (1 332)
Change in Risk Adjustment for non-
financial risk that relates to expired risk – (121) – (121) – (246) – (246)
Experience adjustments 15 – – 15 362 – – 362
Changes that relate to future services
Contracts initially recognised in the
period (1 404) 257 1 351 204 (2 192) 471 2 128 407
Changes in estimates that adjust CSM (97) 8 89 – (164) (2) 166 –
Changes in estimates that result in
onerous contract losses or reversal of
losses 26 7 – 33 345 9 – 354
Insurance service result B (1 460) 151 725 (584) (1 649) 232 962 (455)
Net finance expenses from insurance
contracts C (1 221) 60 164 (997) (2 178) (39) 298 (1 919)
Net changes to income statement
and OCI D = B + C (2 681) 211 889 (1 581) (3 827) 193 1 260 (2 374)
Cash flows E (527) – – (527) (1 553) – – (1 553)
Effect of movements in exchange rates F 3 381 (227) (1 345) 1 809 (1 892) 130 778 (984)
Net balance at the end of the period G = A + D + E + F (37 918) 2 546 14 893 (20 479) (38 091) 2 562 15 349 (20 180)
Closing assets arising from insurance
contracts issued (37 918) 2 546 14 893 (20 479) (38 091) 2 562 15 349 (20 180)
Net balance at the end of the period (37 918) 2 546 14 893 (20 479) (38 091) 2 562 15 349 (20 180)
52 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 53
C. Insurance and reinsurance contracts related disclosure continued
-- 48 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.4 Movement in insurance contract balances: VFA
C.1.2.4.1 SA Invest (participating)
ANALYSIS OF MEASUREMENT COMPONENT
December 2025 June 2025
CSM CSM
Group
R million (Assets)/Liabilities Navigation
Estimates
of PVFCF
RA for non-
financial
Risk
Transition:
Modified
retro-
spective
Other
contracts Total
Estimates
of PVFCF
RA for non-
financial
Risk
Transition:
Modified
retro-
spective
Other
contracts Total
Opening liabilities arising from
insurance contracts issued 80 199 843 5 377 1 731 88 150 66 642 773 5 275 1 031 73 721
Net balance at beginning of the
period A 80 199 843 5 377 1 731 88 150 66 642 773 5 275 1 031 73 721
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided – – (515) (203) (718) – – (1 058) (266) (1 324)
Change in Risk Adjustment for non-
financial risk that relates to expired risk – (79) – – (79) – (186) – – (186)
Experience adjustments (40) – 9 (1) (32) (96) – 56 (22) (62)
Changes that relate to future services
Contracts initially recognised in the
period (285) 36 – 270 21 (764) 89 – 732 57
Changes in estimates that adjust CSM (1 064) 69 738 257 – (357) 99 202 56 –
Changes in estimates that result in
onerous contract losses or reversal
of losses (20) – – – (20) 6 1 – – 7
Insurance service result B (1 409) 26 232 323 (828) (1 211) 3 (800) 500 (1 508)
Net finance expenses from insurance
contracts C 10 796 31 405 122 11 354 11 855 67 902 200 13 024
Net changes to income statement
and OCI D = B + C 9 387 57 637 445 10 526 10 644 70 102 700 11 516
Cash flows E 2 043 – – – 2 043 2 913 – – – 2 913
Net balance at the end of the period G = A + D + E 91 629 900 6 014 2 176 100 719 80 199 843 5 377 1 731 88 150
Closing liabilities arising from insurance
contracts issued 91 629 900 6 014 2 176 100 719 80 199 843 5 377 1 731 88 150
Net balance at the end of the period 91 629 900 6 014 2 176 100 719 80 199 843 5 377 1 731 88 150
54 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 55
C. Insurance and reinsurance contracts related disclosure continued
-- 49 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.5 Movement in reinsurance contract balances: GMM
C.1.2.5.1 SA Life (risk)
ANALYSIS BY MEASUREMENT COMPONENT
December 2025 June 2025
CSM CSM
Group
R million (Assets)/Liabilities Navigation
Estimates
of PVFCF
RA for non-
financial
Risk
Transition:
Modified
retro-
spective
Other
contracts Total
Estimates
of PVFCF
RA for non-
financial
Risk
Transition:
Modified
retro-
spective
Other
contracts Total
Opening liabilities arising from
reinsurance contracts held 5 649 (671) (104) (4 504) 370 5 899 (703) (100) (4 970) 126
Net balance at beginning of the
period A 5 649 (671) (104) (4 504) 370 5 899 (703) (100) (4 970) 126
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided – – 3 161 164 – – 6 319 325
Change in Risk Adjustment for
non-financial risk that relates to expired
risk – 33 – – 33 – 73 – – 73
Experience adjustments 346 – – – 346 624 – – – 624
Changes that relate to future services –
Contracts initially recognised in the
period 121 (13) – (113) (5) 187 (21) – (172) (6)
Changes in estimates that adjust CSM 60 5 – (54) 11 (897) 76 3 839 21
Changes in estimates that relate to
losses and reversal of losses on
underlying contracts (36) 2 – – (34) (19) (2) – – (21)
Changes that relate to past services
Adjustment to assets for incurred claims – – – – – – (1) – – (1)
Net Expenses from reinsurance
contracts held B 491 27 3 (6) 515 (105) 125 9 986 1 015
Net finance income from reinsurance
contracts C 916 (74) (6) (194) 642 1 035 (93) (13) (520) 409
Net changes to income statement
and OCI D = B + C 1 407 (47) (3) (200) 1 157 930 32 (4) 466 1 424
Cash flows E (765) – – – (765) (1 180) – – – (1 180)
Effect of movements in exchange rates F – – – – – – – – – –
Net balance at the end of the period G = A + D + E + F 6 291 (718) (107) (4 704) 762 5 649 (671) (104) (4 504) 370
Closing liabilities arising from
reinsurance contracts held 6 291 (718) (107) (4 704) 762 5 649 (671) (104) (4 504) 370
Net balance at the end of the period 6 291 (718) (107) (4 704) 762 5 649 (671) (104) (4 504) 370
56 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 57
C. Insurance and reinsurance contracts related disclosure continued
-- 50 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.5 Movement in reinsurance contract balances: GMM continued
C.1.2.5.2 UK Life (risk)
ANALYSIS BY MEASUREMENT COMPONENT
December 2025 June 2025
RA for non-
financial
Risk
CSM CSM
Group
R million (Assets)/Liabilities Navigation
Estimates of
VFCF
Other
contracts Total
Estimates of
PVFCF
RA for
non-financial
Risk
Other
contracts Total
Opening liabilities arising from
reinsurance contracts held 17 023 (521) (7 751) 8 751 11 460 (471) (5 719) 5 270
Net balance at beginning of the
period A 17 023 (521) (7 751) 8 751 11 460 (471) (5 719) 5 270
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided – – 360 360 – – 636 636
Change in Risk Adjustment for non-
financial risk that
relates to expired risk – 3 – 3 – 25 – 25
Experience adjustments 153 – – 153 (130) – – (130)
Changes that relate to future services
Contracts initially recognised in the
period 780 (42) (881) (143) 1 574 (76) (1 782) (284)
Changes in estimates that adjust CSM (98) – 109 11 333 (2) (331) –
Changes in estimates that relate to
losses and reversal of losses on
underlying contracts (5) (2) – (7) (81) (4) – (85)
Net Expenses from reinsurance
contracts held B 830 (41) (412) 377 1 696 (57) (1 477) 162
Net finance income from reinsurance
contracts C 397 (16) (106) 275 598 34 (180) 452
Net changes to income statement
and OCI D = B + C 1 227 (57) (518) 652 2 294 (23) (1 657) 614
Cash flows E 1 006 – – 1 006 2 460 – – 2 460
Effect of movements in exchange rates F (1 547) 47 683 (817) 809 (27) (375) 407
Net balance at the end of the period G = A + D + E + F 17 709 (531) (7 586) 9 592 17 023 (521) (7 751) 8 751
Closing liabilities arising from
reinsurance contracts held 17 709 (531) (7 586) 9 592 17 023 (521) (7 751) 8 751
Net balance at the end of the period 17 709 (531) (7 586) 9 592 17 023 (521) (7 751) 8 751
58 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 59
C. Insurance and reinsurance contracts related disclosure continued
-- 51 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.6 Insurance revenue
The following tables present an analysis of the insurance revenue recognised in the period.
Group
R million Income/(expense)
SA Life Risk
(GMM)
SA Invest
Risk (GMM)
SA Invest
Participating
(VFA)
SA Life: Group
life and other
(PAA)
SA Insure
and other
(PAA)
UK Life Risk
(GMM)1
UK Health
(PAA) Total
Six months ended 31 December 2025
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 6 781 515 1 398 – – 2 742 – 11 436
– CSM recognised for services provided 1 052 166 718 – – 715 – 2 651
– Change in risk adjustment for non-financial risk for risk expired 310 26 79 – – 117 – 532
– Expected incurred claims and other insurance service expenses 5 410 308 574 – – 1 955 – 8 247
– Experience adjustments 9 15 27 – – (45) – 6
Recovery of insurance acquisition cash flows 1 131 91 395 – – 1 687 – 3 304
Contracts not measured under the PAA 7 912 606 1 793 – – 4 429 – 14 740
Contracts measured under the PAA – – – 1 890 3 572 – 10 498 15 960
Total insurance revenue 7 912 606 1 793 1 890 3 572 4 429 10 498 30 700
Six months ended 31 December 2024
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 6 617 480 1 218 – – 2 334 – 10 649
– CSM recognised for services provided 935 198 613 – – 641 – 2 387
– Change in risk adjustment for non-financial risk for risk expired 294 17 69 – – 115 – 495
– Expected incurred claims and other insurance service expenses 5 351 262 495 – – 1 703 – 7 811
– Experience adjustments 37 3 41 – – (125) – (44)
Recovery of insurance acquisition cash flows 972 121 389 – – 1 424 – 2 906
Contracts not measured under the PAA 7 589 601 1 607 – – 3 758 – 13 555
Contracts measured under the PAA – – – 1 853 3 405 – 9 112 14 370
Total insurance revenue 7 589 601 1 607 1 853 3 405 3 758 9 112 27 925
60 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 61
C. Insurance and reinsurance contracts related disclosure continued
-- 52 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.7 Net investment result
The following table analyses the Group’s net investment result in profit or loss and OCI.
Group
R million (Income/(expense))
SA Life Risk
(GMM)
SA Invest
Risk (GMM)
SA Invest
Participating
(VFA)
SA Life:
Group Life
and other
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)
UK Health
(PAA)
Other
businesses Total
Six months ended 31 December 2025
Investment return
Interest revenue from financial assets not measured at FVTPL 11 – 18 – 2 33 91 371 526
Net gains on FVTPL investments 35 2 618 11 438 235 – – 28 7 909 22 263
Total investment return 46 2 618 11 456 235 2 33 119 8 280 22 789
Movement in investment contract liabilities – – – – – – – (3 338) (3 338)
Movement in third party interests in consolidated funds – – – – – – – (4 068) (4 068)
Finance income/(expenses) from insurance contracts
Amounts recognised in profit or loss 1 600 (2 645) (11 354) (230) (19) 316 – – (12 332)
– Changes in fair value of underlying items of direct participation contracts – – (11 354) – – – – – (11 354)
– Interest accreted to the CSM (1 577) (37) (527) – – (154) – – (2 295)
– Interest on FCF and other finance (income)/expenses 3 177 (769) 527 (230) (19) 470 – – 3 156
– Effect of changes in interest rates and other financial assumptions – (1 839) – – – – – – (1 839)
Amounts recognised in OCI 8 280 – – (215) – 681 – – 8 746
– Interest accreted to the CSM 257 – – – – (10) – – 247
– Interest on FCF and other finance (income)/expenses (1 244) – – 35 – 153 – – (1 056)
– Effect of changes in interest rates and other financial assumptions 9 208 – – (260) – 577 – – 9 525
– Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 171 – – – – (39) – – 132
– Effect of movements in exchange rates (112) – – 10 – – – – (102)
Net finance expenses from insurance contracts 9 880 (2 645) (11 354) (445) (19) 997 – – (3 586)
Finance income/(expenses) from reinsurance contracts
Amounts recognised in profit or loss 31 – – 28 – (197) – – (138)
– Interest accreted to the CSM 229 – – – – 99 – – 328
– Interest on FCF and other finance (income)/expenses (198) – – 28 – (296) – – (466)
Amounts recognised in OCI (673) – – 27 – (78) – – (724)
– Interest accreted to the CSM (20) – – – – 6 – – (14)
– Interest on FCF and other finance (income)/expenses 3 – – (3) – (45) – – (45)
– Effect of changes in interest rates and other financial assumptions (700) – – 30 – (33) – – (703)
– Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 39 – – – – (6) – – 33
– Effect of movements in exchange rates 5 – – – – – – – 5
Net finance Income from reinsurance contracts (642) – – 55 – (275) – – (862)
62 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 63
C. Insurance and reinsurance contracts related disclosure continued
-- 53 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.7 Net investment result continued
Group
R million Income/(expense)
SA Life Risk
(GMM)
SA Invest
Risk (GMM)
SA Invest
Participating
(VFA)
SA Life:
Group Life
and other
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)
UK Health
(PAA)
Other
businesses Total
Six months ended 31 December 2024
Investment return
Interest revenue from financial assets not measured at FVTPL 2 – – – 133 41 45 240 461
Net gains on FVTPL investments (42) 1 693 5 954 270 8 – 60 4 694 12 637
Total investment return (40) 1 693 5 954 270 141 41 105 4 934 13 098
Movement in investment contract liabilities – – – – – – – (1 919) (1 919)
Movement in third party interests in consolidated funds – – – – – – – (2 401) (2 401)
Finance income/(expenses) from insurance contracts
Amounts recognised in profit or loss 1 578 (1 596) (5 904) (242) – 272 – – (5 892)
– Changes in fair value of underlying items of direct participation contracts – – (5 895) – – – – – (5 895)
– Interest accreted to the CSM (1 630) (42) (540) – – (117) – – (2 329)
– Interest on FCF and other finance (income)/expenses 3 208 (892) 531 (242) – 389 – – 2 994
– Effect of changes in interest rates and other financial assumptions – (662) – – – – – – (662)
Amounts recognised in OCI 2 400 – – (22) – 433 – – 2 810
– Interest accreted to the CSM 310 – – – – (14) – – 296
– Interest on FCF and other finance (income)/expenses (1 201) – – 41 – 298 – – (862)
– Effect of changes in interest rates and other financial assumptions 3 529 – – (59) – 81 – – 3 551
– Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition (292) – – – – 68 – – (224)
– Effect of movements in exchange rates 54 – – (5) – – – – 49
Net finance expenses from insurance contracts 3 978 (1 596) (5 904) (264) – 705 – – (3 081)
Finance income/(expenses) from reinsurance contracts
Amounts recognised in profit or loss (94) – – 31 – (127) – – (190)
– Interest accreted to the CSM 248 – – – – 68 – – 316
– Interest on FCF and other finance (income)/expenses (342) – – 31 – (195) – – (506)
Amounts recognised in OCI (41) – – 5 – (54) – – (90)
– Interest accreted to the CSM (19) – – – – 7 – – (12)
– Interest on FCF and other finance (income)/expenses 175 – – (4) – (126) – – 45
– Effect of changes in interest rates and other financial assumptions (312) – – 4 – 75 – – (233)
– Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 118 – – – – (10) – – 108
– Effect of movements in exchange rates (3) – – 5 – – – – 2
Net finance Income from reinsurance contracts (135) – – 36 – (181) – – (280)
64 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 65
C. Insurance and reinsurance contracts related disclosure continued
-- 54 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.8 Effect of contracts initially recognised in the period
Insurance contracts
Group
R million Assets/(Liabilities)
Profitable contracts issued Onerous contracts issued
SA Life Risk
(GMM)
SA Invest
Risk (GMM)
SA Invest
Participating
(VFA)
UK Life Risk
(GMM)
SA Life Risk
(GMM)
SA Invest
Risk (GMM)
SA Invest
Participating
(VFA)
UK Life Risk
(GMM) Total
Six months ended 31 December 2025
Insurance acquisition cash flows (813) (48) (320) (2 853) (61) (8) (58) (668) (4 829)
Claims and other insurance service expenses payable (1 305) (1 097) (4 813) (4 364) (126) (159) (924) (1 447) (14 235)
Estimates of present value of cash outflows (2 118) (1 145) (5 133) (7 217) (187) (167) (982) (2 115) (19 064)
Estimates of present value of cash inflows 3 182 1 237 5 436 8 786 174 168 964 1 950 21 897
Risk adjustment for non-financial risk (218) (6) (33) (218) (11) (5) (3) (39) (533)
CSM (846) (86) (270) (1 351) – – – – (2 553)
Losses recognised on initial recognition – – – – (24) (4) (21) (204) (253)
Six months ended 31 December 2024
Insurance acquisition cash flows (755) (79) (268) (2 299) (42) (7) (40) (511) (4 001)
Claims and other insurance service expenses payable (1 223) (1 812) (4 325) (3 328) (83) (194) (599) (1 210) (12 774)
Estimates of present value of cash outflows (1 978) (1 891) (4 593) (5 627) (125) (201) (639) (1 721) (16 775)
Estimates of present value of cash inflows 2 985 2 034 4 988 6 871 118 192 628 1 589 19 405
Risk adjustment for non-financial risk (198) (10) (31) (197) (8) (4) (8) (34) (490)
CSM (809) (133) (364) (1 047) – – – – (2 353)
Losses recognised on initial recognition – – – – (15) (13) (19) (166) (213)
66 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 67
C. Insurance and reinsurance contracts related disclosure continued
-- 55 of 81 --
C.1.2 INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.1.2.8 Effect of contracts initially recognised in the period continued
Reinsurance contracts
Group
R million Assets/(Liabilities)
Group of contracts with a net
cost on initial recognition1
SA Life Risk
(GMM)
UK Life Risk
(GMM) Total
Six months ended 31 December 2025
Estimates of present value of cash outflows (654) (7 321) (7 975)
Estimates of present value of cash inflows 533 6 541 7 074
Risk adjustment for non-financial Risk 13 42 55
Income recognised on initial recognition (for offset) (5) (143) (148)
CSM (113) (881) (994)
Six months ended 31 December 2024
Estimates of present value of cash outflows (576) (4 760) (5 336)
Estimates of present value of cash inflows 460 3 955 4 415
Risk adjustment for non-financial Risk 12 26 38
Income recognised on initial recognition (for offset) (3) (114) (117)
CSM (107) (893) (1 000)
1 Group of contracts with a net cost on initial recognition refers to those reinsurance contracts with a CSM on initial recognition, that will reflect as a future
cost relative to the insurance contract CSM that will release as future revenue.
68 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
C. Insurance and reinsurance contracts related disclosure continued
-- 56 of 81 --
S E C T I O N D
Adoption of new
standards and
interpretations and
restatements
70 D.1 Restatement as a result of prior period
errors identified
69
-- 57 of 81 --
The section provides information on the material new standards, amendments and interpretations that became effective for
Discovery for its financial period commencing 1 July 2025. In addition, the section sets out the correction of prior period errors
and the changes in presentation of specified line items.
New standards and interpretation that became effective
For the financial period commencing 1 July 2025, there were no material new standards, amendments or interpretations that
became effective for Discovery.
D.1 RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED
During the preparation of financial statements, management may identify prior period errors arising from miscalculations,
oversights or the misapplication of information available at the time. There were no such errors identified during the period
under review. As previously reported for the financial year ended 30 June 2025, management identified prior period errors
requiring correction and accordingly restated the affected prior period information. As a result, the prior period information for
the six months ended 31 December 2024, as presented in these results, has accordingly been restated.
This section provides summary information of the impact of the prior period information in line with the the previously
communicated full year restatements. The corrections impacted the Group Income statement and Group Statement of other
comprehensive income for the six months ended 31 December 2024 and the Group Statement of cash flows for the six months
ended 31 December 2024. The information is set out to reconcile the previously published information to the final restated
financial positions and performance.
ITEM 1: CORRECTION OF SA LIFE AND SA INVEST INSURANCE RESULTS
Discovery adopted IFRS 17 Insurance Contracts for the first time, with full retrospective effect, in the financial year ended 30 June
2024. During the 30 June 2025 review, Discovery identified the need to correct a coding error that impacted the quantification of
the transitional impact of IFRS 17. This error affected the way in which the SA Life and SA Invest businesses accounted for
changes in estimates. The correction resulted in a reallocation from the Insurance Finance Reserve, a component of equity, with
a resultant increase in the Contractual Service Margin (CSM).
As explained during transition to IFRS 17, the positive increase in CSM represents a “store of value” that is expected to release to
the income statement, and ultimately to equity as retained earnings, over time. The CSM releases to the income statement as
services are provided based on the coverage units of the underlying groups of insurance contracts.
Notably, the strengthening of the CSM resulted in a decrease in the number of groups classified as onerous. The decrease in the
onerous contract groups resulted in an increase in retained earnings as well as an increase in earnings of the prior year.
The other measurement components of insurance contract balances, namely the present value of fulfilment cash flows and the
risk adjustment, were unaffected by this correction. Importantly, the correction had a cumulative impact on the later years of the
fully retrospective transition.
The restatement for the six months ended 31 December 2024 had no effect on operating, investing, or financing cash flows.
While there was no overall impact on cash flows from operating activities, the correction resulted in an increase of R223 million
in cash generated from operations, with an equal and opposite adjustment to operating liabilities. Consistent with the impacts
explained upon transition, the restatement does not affect regulatory solvency positions or embedded value.
RECONCILIATION OF GROUP INCOME STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 20241
R million
Group
31 December
2024
(previously
reported)
Item 1
Correction
Increase/
(Decrease)
Group
31 December
2024
Restated
Insurance revenue 27 774 151 27 925
Insurance service expenses (23 681) 198 (23 483)
Net income/(expenses) from reinsurance contracts (816) (50) (866)
Insurance service result 3 277 299 3 576
Net financial result from insurance finance income and expense (6 006) (76) (6 082)
– Net finance income/(expense) from insurance contracts (5 807) (85) (5 892)
– Net finance income/(expense) from reinsurance contracts (199) 9 (190)–
Net insurance and investment results 6 040 223 6 263
Fee income from administration business 7 314 – 7 314
Non-insurance revenue and income 12 088 – 12 088
Net income 18 128 223 18 351
Non-insurance acquisition costs (600) – (600)
Operating profit 6 877 223 7 100
Profit before financing and income tax 7 250 223 7 473
Profit before income tax 6 169 223 6 392
Income tax expense (1 840) (60) (1 900)
Profit for the year 4 329 163 4 492
1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items
from the Group income statement.
70 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
D. Adoption of new standards and interpretations and restatements
-- 58 of 81 --
D.1 RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED continued
RECONCILIATION OF GROUP STATEMENT OF OTHER COMPREHENSIVE INCOME FOR THE SIX MONTHS ENDED
31 DECEMBER 20241
R million
Group
31 December
2024
(previously
reported)
Item 1
Correction
Increase/
(Decrease)
Group
31 December
2024
Restated
Profit for the year 4 329 163 4 492
Net finance income/(expense) from insurance contracts issued 2 611 (551) 2 060
– Unrealised income/(expense) 3 565 (755) 2 810
– Tax on unrealised (income)/expense (954) 204 (750)
Net finance (expense)/income from reinsurance contracts held (117) 50 (67)
– Unrealised (expense)/income (158) 68 (90)
– Tax on unrealised expense/(income) 41 (18) 23
Total income and expenses that will be reclassified to profit or loss
when specific conditions are met 3 332 (501) 2 831
Other comprehensive income for the year, net of tax 3 327 (501) 2 826
Total comprehensive income for the year 7 656 (338) 7 318
1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items
from the Group statement of other comprehensive income.
ITEM 2: CORRECTION OF THE NON-INSURANCE ACQUISITION COSTS FOR DISCOVERY INVEST
During the year ended 30 June 2025, Discovery identified that it had not eliminated the reimbursement of the acquisition
costs incurred within the SA Invest segment. This incorrect treatment resulted in an overstatement of the fee income from
administration business and overstatement in non-insurance acquisition costs in the period ended 31 December 2024.
The correction does not impact the Group income statement’s total profit, basic earnings per share, or diluted earnings per
share. The restatement has had no impact on operating, investing, or financing cash flows.
RECONCILIATION OF GROUP INCOME STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 20241
R million
Group
31 December
2024
(post item 1
correction)
Item 2
Correction
Increase/
(Decrease)
Group
31 December
2024
Restated
Fee income from administration business 7 314 (283) 7 031
Non-insurance revenue and income 12 088 (283) 11 805
Net income 18 351 (283) 18 068
Non-insurance acquisition costs (600) 283 (317)
Operating profit 7 100 – 7 100
Profit before financing and income tax 7 473 – 7 473
Profit before income tax 6 392 – 6 392
Income tax expense (1 900) – (1 900)
Profit for the year 4 492 – 4 492
1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items
from the Group income statement.
ITEM 3: GROUP STATEMENT OF CASH FLOWS
Discovery regularly reviews its presentation and disclosures in line with evolving market practices, IFRS Accounting Standards,
and changes in its business to enhance clarity and understanding. During the June 2025 review, the Group has updated its
statement of cash flows, applying the changes to the six month period ended 31 December 2025 and restating the prior year for
comparability, with a reconciliation provided between the originally published 2024 figures and the restated balances.
Previously, changes in ‘Fair value adjustments to liabilities under investment contracts’ and ‘Third-party interest: fair value
adjustment to liabilities under investment contracts’ were recorded as cash outflows in Cash generated from operations with a
corresponding entry within changes in operating liabilities. These fair value adjustments are now appropriately recognised as
non-cash movements, with an equal and opposite change to the operating liabilities. In addition, the method for determining
realised gains and losses on investments has been revised, and the prior year corrected accordingly. Importantly, the
restatements have no impact on total ‘Cash flows from operating activities’, as reflected below.
71
-- 59 of 81 --
D.1 RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED continued
RECONCILIATION OF GROUP STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED 31 DECEMBER 20241
R million
Group
December
2024
As previously
published,
including
correction of
item 1 as set
out above
Item 3
Correction
Increase/
(Decrease)
Group
Restated
December 2024
Cash flow from operating activities 3 546 – 3 546
Cash generated by operations (1 174) 1 659 485
Net movement in operating assets and liabilities 5 727 (1 659) 4 068
– Increase in operating assets (7 666) 2 661 (5 005)
– Increase in operating liabilities 13 393 (4 320) 9 073
1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items
from the Group statement of cash flows.
72 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
D. Adoption of new standards and interpretations and restatements
continued
-- 60 of 81 --
S E C T I O N E
Accounting policies
74 E.1 New accounting standards and amendments
to published accounting standards not yet
effective
74 E.2 Normalised headline earnings
75 E.3 Basis of preparation
73
-- 61 of 81 --
E.1 NEW ACCOUNTING STANDARDS AND AMENDMENTS TO PUBLISHED
ACCOUNTING STANDARDS NOT YET EFFECTIVE
Discovery has not early adopted any other IFRS Accounting Standards, amendments or interpretations that have been issued
but not yet effective and have a material impact on Discovery. Discovery does not expect any new IFRS Accounting Standards,
amendments or interpretations that have been issued but not yet effective to have a material impact on the recognised amounts
except for IFRS 18 Presentation and disclosure in Financial Statements (IFRS 18), which supersedes IAS 1 Presentation of Financial
Statements (IAS 1) and provides additional requirements for the presentation and disclosure of information in the primary
financial statements and the notes to improve transparency and comparability of information. For Discovery, IFRS 18 will be
effective from 1 July 2027. Discovery is assessing additional disclosure requirements required.
Interest Rate Benchmark Reforms (IBOR)
In recent years, major interest rate benchmarks have been reformed globally, including the replacement of certain interbank
offered rates (IBORs) with alternative nearly risk-free rates (referred to as “IBOR reform”). Discovery has financial instruments
that have been or will be affected by these market-wide changes, most notably the transition from LIBOR to Sterling Overnight
Index Average (SONIA) in the UK and the upcoming replacement of Johannesburg Interbank Average Rate (JIBAR) with South
African rand Overnight Index Average Rate (ZARONIA).
Following an observation period from 1 November 2022 to 31 October 2023, ZARONIA was identified and endorsed as JIBAR’s
successor. The South African Reserve Bank (SARB) has confirmed that the JIBAR will be permanently discontinued after its final
publication on 31 December 2026. Several key milestones leading up to the cessation are outlined in the industry timeline
published by the SARB, including:
■ November 2024 – ZARONIA-first for derivatives
■ June 2025 – ZARONIA-first for the cash market
■ March 2026 – No new JIBAR
Discovery has the current following JIBAR-linked exposures as at 31 December 2025:
■ SA Bank borrowings, with associated interest rate derivatives, as detailed in Note A.5.2.
■ Investments of c. R9.3 billion.
■ Home loans provided to customers of c. R2.9 billion.
Discovery will apply the same transition relief under IFRS Accounting Standards as it did when transitioning from LIBOR to
SONIA.
IBOR reforms generally result in changes to the basis for determining the contractual cash flows of financial assets and liabilities,
including derivatives.
For financial assets and liabilities measured at amortised cost, the entity will update the effective interest rate without
recognising a gain or loss, provided that:
■ The change is a direct consequence of IBOR reform, and
■ The new basis for determining contractual cash flows is economically equivalent to the previous basis.
For cash flow hedges, when assessing whether a forecast transaction remains highly probable, an entity will assume that the
interest rate benchmark on which the hedged cash flows are based remains unchanged as a result of IBOR reform.
E.2 NORMALISED HEADLINE EARNINGS
Discovery assesses its performance using normalised headline earnings, an alternative profit measure not under the IFRS
Accounting Standards, alongside its IFRS Accounting Standards profit measures. Management considers that Normalised
Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the comparability and
understanding of the financial performance of the Group.
Measures not in terms of IFRS Accounting Standards are not uniformly defined or used by all entities and may not be
comparable with similarly labelled measures and disclosures provided by other entities.
Discovery calculates headline earnings in accordance with the latest SAICA circular: ’Headline Earnings’. NHEPS is calculated by
starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal
operations as follows:
■ Once-off transactions – for example, restructuring costs, transaction costs related to interest rate derivatives and initial
deferred tax assets raised on previously unrecognised assessed losses
■ Unusual items – the Group considers items to be unusual when they have limited predictive value, or it is reasonable that
items of a similar nature would not necessarily arise for several future reporting periods
■ Income or expenses not considered to be part of the Group’s normal operations – for example, amortisation of intangibles
from business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges
Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the
policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency.
74 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
E. Accounting policies
-- 62 of 81 --
E.3 BASIS OF PREPARATION
Statement of compliance
Discovery Limited is a company incorporated in South Africa.
The unaudited condensed consolidated interim financial statements for the six months ended 31 December 2025 (interim
results) consolidate the results of Discovery and its subsidiaries (together the Group) and equity account the Group’s interests in
associates and joint ventures.
The interim results comprise the Group statement of financial position as at 31 December 2025, the Group income statement,
the Group statement of other comprehensive income, the Group statement of changes in equity and the Group statement of
cash flows for the six months ended 31 December 2025 and selected explanatory notes.
The interim results have been prepared in accordance with the JSE Listings Requirements, IFRS® Accounting Standards as issued
by the International Accounting Standards Board (IFRS Accounting Standards), including IAS 34 Interim Financial Reporting (IAS 34),
the South African Institute of Chartered Accountants (SAICA) Financial Reporting Guides as issued by the Accounting Practices
Committee and Financial Pronouncements as issued by the Financial Reporting Standards Council (FRSC) and the requirements
of the Companies Act of South Africa.
The accounting policies adopted are consistent with the accounting policies applied in the prior Annual Financial Statements.
External assurance and comparative information
The financial information in these interim results, as well as the comparative information for the six months ended
31 December 2024, have not been reviewed or audited by the Group's independent external auditors, KPMG Inc. and Deloitte &
Touche. Comparative information presented as at and for the year ended 30 June 2025 within these financial statements has
been extracted from the Group’s audited consolidated financial statements for the year ended 30 June 2025 but is not itself
audited.
These interim results do not include all the notes typically included in the annual financial statements and must be read together
with the Group's audited consolidated financial statements for the year ended 30 June 2025. The Board of Discovery takes full
responsibility for the accuracy of the extracted information.
75
-- 63 of 81 --
Embedded value
statement
78 Table 1: Group embedded value
80 Table 2: Value of in-force covered business
81 Table 3: Group embedded value earnings
81 Table 4: Components of Group embedded value
earnings
82 Table 5: Experience variances
83 Table 6: Methodology and assumption changes
84 Table 7: Value of new business
86 Table 8: Embedded value economic assumptions
88 Table 9: Embedded value sensitivity
88 Table 10: Value of new business sensitivity
76 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
-- 64 of 81 --
The embedded value of the Discovery Group consists of the following components:
■ the adjusted net worth attributed to the business at the valuation date;
■ plus: the present value of expected future shareholder cash flows from the in-force covered business;
■ less: the cost of required capital.
The present value of expected future shareholder cash flows from the in-force covered business is calculated as the value of projected
after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities,
whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected after-tax shareholder cash flows of the new business
written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and cost of
required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business
includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and Discovery
Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health Insurance, Discovery
Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current inforce business.
In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible
preference shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
77
Embedded value statement
for the period ended 31 December 2025
-- 65 of 81 --
TABLE 1: GROUP EMBEDDED VALUE
R million
31 December
2025
31 December
2024 % Change
30 June
2025
Shareholders’ funds 73 438 64 644 14 65 699
Adjustment to shareholders’ funds from published basis1 (47 395) (42 525) 11 (40 660)
Adjusted net worth2 26 043 22 119 18 25 039
Value of in-force covered business before cost of required capital 113 087 100 803 12 104 812
Cost of required capital (3 286) (3 306) (1) (3 297)
Discovery Group embedded value 135 844 119 616 14 126 554
Number of shares (millions) 672.6 666.5 666.6
Embedded value per share R201.97 R179.47 13 R189.85
Diluted number of shares (millions) 672.7 667.1 668.7
Diluted embedded value per share3 R201.92 R179.29 13 R189.25
1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the closing exchange
rate of R22.27/GBP (June 2025: R24.34/GBP; December 2024: R23.61/GBP).
R million
31 December
2025
31 December
2024
30 June
2025
Life net assets under insurance contracts (28 357) (23 982) (21 333)
Vitality Life Limited net assets under insurance contracts (11 692) (11 179) (11 663)
VitalityHealth Insurance Acquisition Cash Flow (IACF) Asset (4 893) (4 673) (5 120)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) (6) (8) (7)
Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture (2 756) (2 922) (3 012)
Intangible assets (net of deferred tax) in covered businesses (707) (807) (813)
Net preference share capital (779) (779) (779)
Reversal of 1 Discovery Place IFRS 16 financial lease accounting 1 581 1 516 1 550
Equity settled share based payment mark-to-market adjustment* 214 309 517
Adjustment to shareholders’ funds from published basis (47 395) (42 525) (40 660)
* The “equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market value of the
equity settled share based payments.
78 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Embedded value statement continued
for the period ended 31 December 2025
-- 66 of 81 --
TABLE 1: GROUP EMBEDDED VALUE continued
2 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value:
R million
31 December
2025
31 December
2024
30 June
2025
Shareholders’ funds 73 438 64 644 65 699
Adjustment to shareholders’ funds (47 395) (42 525) (40 660)
Adjusted net worth 26 043 22 119 25 039
Excess of available capital over adjusted net worth 56 891 51 754 52 419
Available capital 82 934 73 873 77 458
Required capital 53 364 48 106 48 446
Excess available capital 29 570 25 767 29 012
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth for embedded value purposes and the available capital on a
statutory solvency basis for covered business. This includes:
– The net preference share capital of R779 million which is included as available capital.
– The difference between Vitality Life Limited’s Solvency UK Pillar 1 Own Funds and its adjusted net worth.
– The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R million
31 December
2025
31 December
2024
30 June
2025
Health and Vitality 1 296 1 280 1 286
Life and Invest 34 751 30 285 29 349
VitalityHealth 4 175 4 348 4 761
VitalityLife 13 142 12 193 13 050
Total required capital 53 364 48 106 48 446
– For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
– For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
– For VitalityHealth, the required capital was set equal to 1.55 times the Solvency UK Pillar 1 Solvency Capital Requirement.
– For VitalityLife, the required capital was set equal to 1.4 times the Solvency UK Pillar 1 Solvency Capital Requirement.
The cost of required capital in the embedded value is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required
capital amount and, where relevant, an internally defined liquidity target capital requirement of tangible assets. As a result, changes in the required capital noted in the table
above may differ from changes in the cost of required capital, where the liquidity target capital requirement of tangible assets is the prevailing constraint. Additional detail is
provided in the ‘basis of preparation’ section.
3 The diluted embedded value per share adjusts for the effect of vested treasury shares, share options exercised, and vesting of share awards where the impact is dilutive.
This adjustment has been aligned to the diluted number of shares shown elsewhere in the financial statements.
79
-- 67 of 81 --
TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS
R million
Value before
cost of capital Cost of capital
Value after
cost of capital
At 31 December 2025
Health and Vitality 30 839 (527) 30 312
Life and Invest1 49 505 (1 656) 47 849
VitalityHealth2 17 472 (441) 17 031
VitalityLife2 15 271 (662) 14 609
Total 113 087 (3 286) 109 801
At 31 December 2024
Health and Vitality 28 345 (524) 27 821
Life and Invest1 41 643 (1 844) 39 799
VitalityHealth2 15 891 (417) 15 474
VitalityLife2 14 924 (521) 14 403
Total 100 803 (3 306) 97 497
At 30 June 2025
Health and Vitality 27 972 (525) 27 447
Life and Invest1 42 869 (1 614) 41 255
VitalityHealth2 18 395 (526) 17 869
VitalityLife2 15 576 (632) 14 944
Total 104 812 (3 297) 101 515
1 Included in the Life and Invest value of in-force covered business is R3 321 million (June 2025: R2 849 million; December 2024: R2 463 million) in respect of investment
management services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R22.27/GBP (June 2025: R24.34/GBP; December 2024: R23.61/GBP).
80 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Embedded value statement continued
for the period ended 31 December 2025
-- 68 of 81 --
TABLE 3: GROUP EMBEDDED VALUE EARNINGS
Six months ended Year ended
R million
31 December
2025
31 December
2024
30 June
2025
Embedded value at end of period 135 844 119 616 126 554
Less: embedded value at beginning of period (126 554) (110 354) (110 354)
Increase in embedded value 9 290 9 262 16 200
Dividends paid 1 407 1 073 1 707
Employee share option schemes (382) (342) (721)
Net change in capital 139 – 23
Transfer to hedging reserve 72 40 104
Acquisition of subsidiaries with non-controlling interest – – (1)
Embedded value earnings 10 526 10 033 17 312
Annualised return on opening embedded value 17.3% 19.0% 15.7%
TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS
Six months ended 31 December 2025
Six months
ended
31 December
2024
Year ended
30 June 2025
R million Net worth
Cost of
required
capital
Value of in-
force covered
business
Embedded
value
Embedded
value
Embedded
value
Total profit from new business
(at point of sale) (3 871) (166) 5 393 1 356 953 2 154
Profit from existing business
– Expected return 4 905 26 294 5 225 5 268 10 878
– Change in methodology and
assumptions1 1 922 (30) 3 787 5 679 1 241 (404)
– Experience variances 569 82 1 766 2 417 1 447 2 905
Impairment, amortisation and fair
value adjustment2 (30) – – (30) (30) (62)
Increase in goodwill and intangibles (179) – – (179) (179) (382)
Non-covered businesses3 1 174 – – 1 174 1 160 2 537
Non-recurring expenses (187) – – (187) (103) (355)
Acquisition costs4 (23) – – (23) (11) (45)
Finance costs5 (1 518) – – (1 518) (1 633) (3 125)
Foreign exchange rate movements6 (1 152) 100 (2 966) (4 018) 1 125 1 550
Other7 (15) – 1 (14) (4) (8)
Return on shareholders' funds5,8 644 – – 644 799 1 669
Embedded value earnings 2 239 12 8 275 10 526 10 033 17 312
1. The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and
economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods, refer to previous embedded value statements). Notably,
over the period a significant reduction in both the South African nominal and real risk-free yield curves was observed, resulting in a material reduction in the implied risk
discount rate curve which was partially offset by a reduction in the implied inflation curve. The change in the South African yield curve environment is responsible for
cR5.2 billion of the total change in methodology and assumptions.
2. This item reflects the amortisation of the intangible assets reflecting banking costs, and system spend and capital expenditure for Cambridge Mobile Telematics in
Discovery Insure.
3. This item includes the profits of non-covered businesses. Head office costs relating to non-covered businesses are included, together with cR92 million of expenses that are
currently incurred by the covered businesses but will ultimately be borne by non-covered businesses. These expenses have therefore been excluded from the embedded
value expense analysis of the relevant covered businesses. In addition, profits of cR117 million from non-covered segments within the covered businesses are included in
this item.
4. Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been written over the
period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore the
costs are not deducted from the value of new business.
5. Finance costs and return on shareholders’ funds are shown gross of intercompany charges (cR707 million at 31 December 2025, R1 351 million at 30 June 2025,
R681 million at 31 December 2024).
6. This item includes foreign exchange gains/(losses) emerging through the income statement, in addition to translation impacts on the cost of required capital and value of
in-force.
7. This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth.
8. The return on shareholders’ funds is shown net of tax and management charges.
81
-- 69 of 81 --
TABLE 5: EXPERIENCE VARIANCES
Health and Vitality Life and Invest VitalityHealth VitalityLife
Six months
ended
31 December
2025
R million Net worth
Value of
in-force Net worth
Value of
in-force Net worth
Value of
in-force Net worth
Value of
in-force Total
Renewal expenses 28 – (17) 3 97 – (10) – 101
Lapses and
surrenders1 6 133 14 30 – 17 (107) 105 198
Mortality and
morbidity2 – – 493 (45) 204 – 102 – 754
Policy alterations3 – (25) (276) 42 – – (5) (52) (316)
Backdated
cancellations – – – – – – – – –
Premium and Fee
Income 81 – (13) 23 35 – (2) 16 140
Inflation-linked
indexation4 – – (3) (25) – – (48) 282 206
Economic5 – – (126) 845 96 – (1) – 814
Tax6 103 – 15 69 (25) – 63 14 239
Reinsurance7 – – – – – – (175) 65 (110)
Maintain modelling
term8 – 169 – 52 – 115 – – 336
Vitality benefits9 55 – – – – – 17 – 72
Other – – (20) 19 – – (12) (4) (17)
Total 273 277 67 1 013 407 132 (178) 426 2 417
1. For Health and Vitality, lapse experience reflects the success of targeted interventions against the one-year stressed lapse assumption introduced in the prior period. For
VitalityLife, the positive experience in the value of in-force from lower than expected lapses was offset by a reduction in the net worth from lower commission clawbacks
and lower lapses on policies with positive reserves on the PAC book of business.
2. For Life and Invest, mortality and morbidity claims experience for the period was better than expected across the Individual Life and Group Life businesses. For VitalityLife,
claims experience was driven by better than expected outcomes on the severe illness and income protection products. For VitalityHealth, this item reflects the net impact of
lower than expected claims and Vitality partner spend, together with higher than expected associated risk premiums, arising from the previously higher price increases
earning through. VitalityHealth policyholders are now receiving lower price increases as claims utilisation has stabilised.
3. For Life and Invest, and VitalityLife, the policy alterations experience reflects policy and benefit adjustments to in-force policies during the period, partially offset by positive
experience on lapses and premium income. For Life and Invest, the underlying experience is showing initial signs of improvement following the implementation of
management actions and when normalising for the effect of lower stress assumptions, initially introduced at 30 June 2024, over the period.
4. For Life and Invest, the experience reflects lower than expected in-period inflation increases on inflation-linked policies on the Individual Life business. For VitalityLife, higher
than expected in-period inflation increases on inflation-linked policies resulted in higher projected premium income. The net worth impact for VitalityLife reflects an
increase in the underlying IFRS 4 reserves on the PAC book of business, driven by higher in-period inflation.
5. For Life and Invest, better than expected unit fund growth in Invest resulted in an improved projected fee income reflected in the value of in-force. For VitalityHealth,
investment return continued to contribute to profitability as interest rates in the UK remain high.
6. The tax variance arises due to the timing difference between the expected tax payments and actual payments.
7. For VitalityLife, higher financial reinsurance repayments made over the period results in a lower outstanding deficit account balance, which is reflected as a positive
variance in the value of in-force and a negative variance in the net worth. In addition, for VitalityLife, higher than expected risk reinsurance premiums contributed to the
negative variance in the net worth.
8. For Health and Vitality, Life and Invest, and VitalityHealth, the projection term is rebased at each reporting period. Therefore, an experience variance arises because the
total term of the in-force covered business is effectively increased by six months.
9. For Health and Vitality, the experience is driven by successful benefit management initiatives in the Vitality business.
82 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Embedded value statement continued
for the period ended 31 December 2025
-- 70 of 81 --
TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES
Health and Vitality Life and Invest VitalityHealth VitalityLife
Six months
ended
31 December
2025
R million Net worth
Value of
in-force Net worth
Value of
in-force Net worth
Value of
in-force Net worth
Value of
in-force Total
Modelling changes1 – (10) (32) (198) – – – 93 (147)
Expenses – – – – – – – – –
Lapses – – – – – – – – –
Mortality and
morbidity – – – – – – – – –
Benefit changes – – – – – – – – –
Vitality – – – – – – – – –
Tax – – – – – – – – –
Economic
assumptions2 – 1 193 183 3 863 – – 40 (25) 5 254
Premium and fee
income3 – 380 – – – – – – 380
Reinsurance and
financing4 – – 362 (219) – – 1 273 (1 308) 108
Other5 – – 92 (23) – – 4 11 84
Total – 1 563 605 3 423 – – 1 317 (1 229) 5 679
1. For Life and Invest, this largely relates to Individual Life modelling updates of management actions valued in past reporting periods. Minor refinements were made to the
membership data used for Vitality. For VitalityLife, this relates to the alignment of cash flow timing on the PAC book of business with VitalityLife, as well as other minor
refinements.
2. For Health and Vitality and Life and Invest, the economic assumptions were updated in line with observed internally derived nominal and real risk-free yield curves at
31 December 2025. Over the period, a significant reduction in both the nominal and real risk-free yield curves was observed, resulting in a material reduction in the
implied risk discount rate curve which was partially offset by a reduction in the implied inflation curve. For Health and Vitality, this also includes the impact of higher than
expected inflation applicable to the administration and managed care fee escalation in 2026. For VitalityLife, this item includes the impact of updating the assumptions
relative to the Solvency UK yield curves and the IFRS interest rates.
3. For Health and Vitality, this item represents an additional administration and managed care fee margin effective for 2026. This additional margin is contractually effective
given a defined level of spend to enhance the services rendered by the administrator.
4. For Life and Invest, the reinsurance and financing item primarily relates to the impact of internal financing arrangements, where the future expected cash flows arising
from part of the negative reserves are monetised to match other positive policy liabilities. For VitalityLife, this item includes the impact of external financing arrangements,
where future expected cash flows arising from part of the negative reserves are monetised to partially fund new business.
5. For Life and Invest, this item mainly relates to impacts arising from the IAS 12 deferred tax liability.
83
-- 71 of 81 --
TABLE 7: VALUE OF NEW BUSINESS
Six months ended Year ended
R million
31 December
2025
31 December
2024 % Change
30 June
2025
Health and Vitality
Gross profit from new business (at point of sale) 640 493 1 095
Cost of required capital (23) (21) (45)
Present value of future profits from new business (at point of sale)
after cost of required capital 617 472 31 1 050
New business annual premium equivalent1 2 766 2 401 15 6 093
Life and Invest
Present value of future profits from new business (at point of sale)2 344 275 535
Cost of required capital (43) (36) (74)
Present value of future profits from new business (at point of sale)
after cost of required capital 301 239 26 461
New business annual premium equivalent3 1 879 1 589 18 3 270
Annualised profit margin4 2.1% 1.9% 1.8%
Annualised profit margin excluding Invest business 4.3% 3.6% 2.1%
VitalityHealth5
Present value of future profits from new business (at point of sale) 282 207 671
Cost of required capital (29) (26) (62)
Present value of future profits from new business (at point of sale)
after cost of required capital 253 181 40 609
New business annual premium equivalent6 1 434 1 199 20 2 564
Annualised profit margin4 2.4% 2.4% 3.1%
VitalityLife
Present value of future profits from new business (at point of sale) 256 103 153
Cost of required capital (71) (42) (119)
Present value of future profits from new business (at point of sale)
after cost of required capital 185 61 203 34
New business annual premium equivalent7 1 245 921 35 2 094
Annualised profit margin4 2.2% 0.9% 0.2%
The term "annual premium equivalent" (“APE”) was disclosed as "annualised premium income" (“API”) in previous reporting periods. The
term was changed to avoid conflict with the new business disclosures in the published financial statements, which reference a different
definition for "new business annualised premium income".
1 Health new business annual premium equivalent is the gross contribution to the medical schemes. The new business annual premium equivalent shown above excludes
premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new business
written during the period but only activated after 31 December 2025. The total Health and Vitality new business annualised premium income written over the period was
R5 700 million (June 2025: R10 119 million; December 2024: R4 970 million).
2 Included in the Life and Invest embedded value of new business is R33 million (June 2025: R49 million; December 2024: -R6 million) in respect of investment management
services provided on off balance sheet investment business. Risk business written prior to the valuation date allows certain Invest business to be written at financially
advantageous terms, the impact of which has been recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after the
valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new
business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies whose
first premium is due after the valuation date.
The new business annual premium equivalent of R1 879 million (single premium APE: R929 million (June 2025: R1 717 million; December 2024: R826 million)) shown above
excludes automatic contribution increases, servicing increases in respect of existing business and Umbrella Funds new business annualised premium income. The total new
business annualised premium income written over the period was R3 596 million (single premium API: R983 million (June 2025: R1 806 million; December 2024:
R867 million)) and is set out in the table below:
84 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Embedded value statement continued
for the period ended 31 December 2025
-- 72 of 81 --
TABLE 7: VALUE OF NEW BUSINESS continued
R million
31 December
2025
31 December
2024
30 June
2025
New business annual premium equivalent 1 879 1 589 3 270
Automatic contribution increases 1 178 1 203 2 219
Servicing increases 411 406 761
Umbrella Funds new business annualised premium income 128 192 383
New business annualised premium income 3 596 3 390 6 633
The new business annual premium equivalent of R1 879 million is split between Life of R411 million (June 2025: R735 million; December 2024: R355 million) and Invest of
R1 468 million (June 2025: R2 535 million; December 2024: R1 234 million).
Single premium Invest business is included at 10% of the value of the single premium. Section 14 transfers for Umbrella Funds are included at 10% of the fund value.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as experience variances and
not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the
Margin multiplied by the Annuity Factor plus the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor are
shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annual premium equivalent
shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect of
new business written during the period but only activated after 31 December 2025.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due
after the valuation date. The new business annual premium equivalent shown above excludes automatic contribution increases and servicing increases in respect of
existing business.
85
-- 73 of 81 --
Basis of preparation
TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS
31 December
2025
31 December
2024
30 June
2025
Beta coefficient 0.75 0.75 0.75
Equity risk premium (%) 3.5 3.5 3.5
Risk discount rate (%)
– Health and Vitality1 11.625 13.875 13.875
– Life and Invest1 11.875 14.375 14.625
– VitalityHealth 6.573 6.573 6.573
– VitalityLife 6.735 6.758 6.734
Rand/GB Pound Exchange Rate
– Closing 22.27 23.61 24.34
– Average 23.29 23.14 23.48
Margin over Expense Inflation to derive medical inflation (%)
South Africa 3.00 3.00 3.00
Expense inflation (%)2
South Africa – Health and Vitality 4.83 6.01 5.66
– Life and Invest 4.77 6.54 6.41
United Kingdom 3.64 3.99 3.72
Pre-tax investment return (%)
South Africa – Cash1 7.75 10.25 10.50
– Life and Invest bonds3 9.25 11.75 12.00
– Health and Vitality bonds3 9.00 11.25 11.25
– Equity 12.75 15.25 15.50
United Kingdom – VitalityHealth risk-free rate 3.95 3.95 3.95
– VitalityLife risk-free rate 4.11 4.13 4.11
– VitalityLife Investment return 5.58 4.92 5.26
Long-term corporation tax rate (%)
South Africa 27 27 27
United Kingdom 25 25 25
VitalityHealth Margin and Annuity Factor assumptions
– Margin (net of tax and cost of capital) (%) 10.60 12.42 10.56
– Annuity Factor 7.81 6.42 7.81
Projection term
– Health and Vitality 20 years 20 years 20 years
– Discovery Life – VIF 40 years 40 years 40 years
– Group Life 20 years 20 years 20 years
– VitalityLife No cap No cap No cap
– VitalityHealth4 20 years 20 years 20 years
1. Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2. The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average inflation
is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation.
3. As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4. The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.
86 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Embedded value statement continued
for the period ended 31 December 2025
-- 74 of 81 --
The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model ("CAPM") approach
with specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk
discount rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and
the observed beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI.
The assumed beta will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a
long time period suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values
reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial
risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience and augmented by future expectations.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery
Group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of
an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to an internally derived nominal yield
curve, which is consistent with the IFRS 17 reporting basis.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the
net investment return assumption.
The risk-free rate assumption for VitalityHealth was based on the single interest rate derived from the Prudential Regulatory Authority yield
curve. VitalityLife has transitioned to the use of full yield curves to represent its risk-free rate assumption following the implementation of
IFRS 17. For consistency, VitalityLife has also transitioned to the use of a market inflation curve from a long-term market view of inflation.
VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the Margin multiplied by the
Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse rates and premium
increases. The Margin assumption reflects assumed profit margins after tax and the cost of required capital. The assumptions underlying
the Annuity Factor and Margin are set at the total book level, taking into account the current experience and future expectations across all
durations of in-force business. The economic components underlying the Annuity Factor are reviewed at each reporting date; the non-
economic components underlying the Annuity Factor and Margin assumptions are reviewed periodically.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible
assets. The Vitality Life Limited required capital amount is assumed to earn the investment return assumption, which is set based on the
return on a portfolio of government and corporate bonds assumed to back the required capital. The Life and Invest cost of required capital
is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required capital amount and an
internally defined liquidity target capital requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107:
Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into
account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 footnote 2.
87
-- 75 of 81 --
Basis of preparation
The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values
reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and
non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been
modelled explicitly. The sensitivity of the embedded value and the embedded value of new business at 31 December 2025 to
changes in the risk discount rate is included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for
management action, such as risk premium increases, where future experience is worse than the base assumptions.
TABLE 9: EMBEDDED VALUE SENSITIVITY
Discovery Group Health and Vitality Life and Invest VitalityHealth VitalityLife
Embedded
value
%
Change R million
Adjusted net
worth
Value
of in-force
Cost of
required
capital
Value
of in-force
Cost of
required
capital
Value
of in-force
Cost of
required
capital
Value
of in-force
Cost of
required
capital
Base 26 043 30 839 (527) 49 505 (1 656) 17 472 (441) 15 271 (662) 135 844
Impact of:
Risk discount rate + 1% 26 043 29 081 (577) 45 248 (1 772) 16 466 (574) 14 238 (748) 127 405 (6)
Risk discount rate – 1% 26 043 32 790 (470) 54 541 (1 512) 18 593 (290) 16 456 (529) 145 622 7
Lapses – 10% 25 884 31 865 (553) 54 125 (1 684) 19 474 (491) 16 246 (745) 144 121 6
Interest rates – 1%1 26 205 31 001 (506) 50 131 (1 726) 18 593 (469) 14 566 (790) 137 005 1
Equity and property market value – 10% 25 984 30 839 (527) 48 440 (1 667) 17 472 (441) 15 271 (662) 134 709 (1)
Equity and property return + 1% 26 043 30 839 (527) 50 001 (1 655) 17 472 (441) 15 271 (662) 136 341 0
Renewal expenses – 10% 26 145 33 820 (488) 50 309 (1 640) 19 140 (441) 15 615 (640) 141 820 4
Mortality and Morbidity – 5% 26 309 30 839 (527) 52 671 (1 523) 21 089 (441) 15 774 (637) 143 554 6
Projection term + 1 year 26 043 31 230 (532) 49 638 (1 670) 17 684 (446) 15 271 (662) 136 556 1
1 All economic assumptions were reduced by 1%.
The following table shows the effect of using different assumptions on the embedded value of new business.
TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY
Health and Vitality Life and Invest VitalityHealth VitalityLife
Value of
new business
%
Change R millions
Value
of in-force
Cost of
required
capital
Value
of in-force
Cost of
required
capital
Value
of in-force
Cost of
required
capital
Value
of in-force
Cost of
required
capital
Base 640 (23) 344 (43) 282 (29) 256 (71) 1 356
Impact of:
Risk discount rate + 1% 588 (25) 235 (46) 213 (38) 151 (80) 998 (26)
Risk discount rate – 1% 699 (20) 470 (39) 358 (20) 377 (57) 1 768 30
Lapses – 10% 680 (25) 467 (43) 443 (34) 379 (81) 1 786 32
Interest rates – 1%1 649 (22) 362 (44) 358 (31) 336 (82) 1 526 13
Equity and property return + 1% 640 (23) 361 (43) 282 (29) 256 (71) 1 373 1
Renewal expenses – 10% 730 (22) 369 (42) 386 (29) 293 (69) 1 616 19
Mortality and Morbidity – 5% 640 (23) 391 (39) 507 (29) 294 (70) 1 671 23
Projection term + 1 year 652 (23) 347 (43) 296 (29) 256 (71) 1 385 2
Acquisition expenses – 10% 660 (23) 444 (43) 302 (29) 393 (71) 1 633 20
1 All economic assumptions were reduced by 1%.
88 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 89
Embedded value statement continued
for the period ended 31 December 2025
-- 76 of 81 --
Annexure A
91 New business annualised premium income
92 Income from non-insurance business lines
92 Cash conversion ratio
90 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
-- 77 of 81 --
This Annexure does not form part of the IFRS results. Discovery assesses its performance using alternative non-IFRS profit and income
measures. These measures enhance the comparability and understanding of the financial performance of the Group.
NEW BUSINESS ANNUALISED PREMIUM INCOME
for the six months ended 31 December 2025
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of
the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, DHMS new
business is attributable to the medical scheme but is under the administration and marketing of Discovery Health which earns a fee in
respect of such services.
New business API, increased by 12% for the six months ended 31 December 2025 when compared to the corresponding prior period.
Group
31 December
2025
Group
31 December
2024
%
Change
Discovery Health1 5 454 4 714 16%
Discovery Life 1 635 1 655 (1%)
Individual Life 1 440 1 440 —%
CEB 195 215 (9%)
Discovery Invest 1 961 1 735 13%
Discovery Insure 646 659 (2%)
Discovery Vitality 246 256 (4%)
New business API from Discovery SA 9 942 9 019 10%
VitalityHealth 1 440 1 326 9%
VitalityLife 1 495 1 101 36%
Ping An Health Insurance (PAHI) own licence 1 149 1 088 6%
New business API from Vitality 4 084 3 515 16%
New business API of Group 14 026 12 534 12%
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and offerings such
as Gap cover and FlexiCare cover. Closed Schemes refer to those restricted to certain employers and industries
Calculation of new business API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single
premium policies. It also includes both automatic contribution increases and servicing increases on existing long-term insurance policies.
The amounts exclude indirect taxes.
The new business API in the table above differs from the embedded value new business disclosures largely as a result of:
■ The timing of inclusion of the policyholders in the calculation of new business API – in the embedded value, new business is included
from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in the table above, new
business is included when the policy has been contractually committed.
■ Inclusion of automatic contribution increases and servicing increases on existing life policies – these are included in the table above but
excluded in the embedded value new business disclosures.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business
disclosures between the embedded value annual premium equivalent and the table above.
91
Annexure A
-- 78 of 81 --
INCOME FROM NON-INSURANCE BUSINESS LINES
for the six months ended 31 December 2025
The table below includes income from business lines and activities not covered by the new business API definition, as outlined in the
previous table. For Discovery Bank, banking fees and commissions are presented net of related expenses. This information differs from
that provided in note A.4, which reflects the gross revenue streams for goods or services within the scope of IFRS 15 Revenue from Contracts
with Customers.
Group
31 December
2025
Group
31 December
2024 Change %
Discovery Health – Income excluded from API measure 811 646 26%
Discovery Bank 1 438 1 100 31%
Discovery Bank – Net banking fee and commission income (NIR) 848 611 39%
Discovery Bank – Net bank interest and similar income (NII)1 590 489 21%
Vitality Global income2 1 318 1 435 (8%)
Vitality Network 831 970 (14%)
Vitality Health International - Other 487 465 5%
Total income from non-insurance business lines 3 567 3 181 12%
1 Refer to A.1 Segment Information.
2 Vitality Global income includes gross recurring and lump sum revenues earned by Vitality Group and solutions revenue from external clients, while that from internal
clients and rewards is specifically excluded.
CASH CONVERSION RATIO
for the six months ended 31 December 2025
Cash conversion is calculated as Operating Cash Flow (per the Group shareholder free cash movement included in the additional analyst
information on Discovery’s website), divided by Normalised profit from operations (IFRS total, excluding the IFRS Reporting Adjustments for
shareholder investment income and fair value gains/(losses)) net of Income tax expense (IFRS total) per A.1 Segment Information. The
Operating Cash Flow includes the net impact of funding sourced from financial reinsurance (whether securitised from new business or the
in-force book), which offsets new business acquisition costs, and the in-period repayments in respect of previous funding taken.
Group
31 December
2025
Group
31 December
2024
Cash conversion ratio 71% 76%
The cash conversion ratio for the prior year has been restated for the correction of prior period errors as disclosed in D.1 and for changes
to segment disclosure (refer A.1 Segment Information “Changes from 1 July 2025"), as well as to allow for the reversal of the IFRS Reporting
Adjustments for shareholder investment income and fair value gains/(losses) to better align Normalised Profit from Operations and
Operating Cash Flow.
92 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025
Annexure A continued
-- 79 of 81 --
Transfer secretaries
Computershare Investor Services (Pty) Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196
Private Bag X9000, Saxonwold, 2132
Sponsors and debt sponsors
Nedbank Corporate and Investment Banking,
a division of Nedbank Limited
Secretary and registered office
AC Ceba (FCG) (F.Inst D)
Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: DSY ISIN: ZAE000022331
JSE share code: DSBP ISIN: ZAE000158564
JSE bond company code: DSYI
1 Discovery Place, Sandton, 2196
PO Box 786722, Sandton, 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors
ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), LM Chiume, VN Fakude1
R Farber, WM Hlahla FN Khanyile, D Macready, KC Ramon, M Schreuder, B Swartzberg*,
BA van Kralingen, DM Viljoen* (Group Chief Financial Officer).
* Executive.
1 Appointed effective 1 September 2025
Debt officer
DM Viljoen
Unaudited interim results
– prepared by L Motsepe-Setiloane, CA(SA), G Pieterse CA(SA), J Symons CA(SA)
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by P Bolink FASSA
– supervised by A Rayner FASSA, FIA
Administration
-- 80 of 81 --
-- 81 of 81 --